WO2014120995A2 - Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity - Google Patents

Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity Download PDF

Info

Publication number
WO2014120995A2
WO2014120995A2 PCT/US2014/013992 US2014013992W WO2014120995A2 WO 2014120995 A2 WO2014120995 A2 WO 2014120995A2 US 2014013992 W US2014013992 W US 2014013992W WO 2014120995 A2 WO2014120995 A2 WO 2014120995A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amine
quinolin
hexyloxy
salt
Prior art date
Application number
PCT/US2014/013992
Other languages
English (en)
French (fr)
Other versions
WO2014120995A3 (en
Inventor
David M. Simpson
Dennis Bryan ZERBY
Ming Lu
Reid W. Von Borstel
Rui Li
Julian READING
Stephen Wolpe
Nureddin AMAN
Original Assignee
Wellstat Therapeutics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020157023305A priority Critical patent/KR102205202B1/ko
Priority to PL14746786T priority patent/PL2950649T3/pl
Priority to RU2015137094A priority patent/RU2677229C2/ru
Priority to NZ709885A priority patent/NZ709885A/en
Priority to EP19201890.1A priority patent/EP3632426A1/en
Priority to HK15112408.4A priority patent/HK1211429B/en
Priority to US14/764,207 priority patent/US10030015B2/en
Priority to EP14746786.4A priority patent/EP2950649B1/en
Priority to DK14746786.4T priority patent/DK2950649T3/da
Priority to CN201480007029.0A priority patent/CN104968200B/zh
Priority to JP2015556146A priority patent/JP6463276B2/ja
Priority to ES14746786T priority patent/ES2790675T3/es
Priority to MX2015009864A priority patent/MX369611B/es
Priority to BR112015018282-8A priority patent/BR112015018282B1/pt
Priority to AU2014212242A priority patent/AU2014212242B2/en
Application filed by Wellstat Therapeutics Corporation filed Critical Wellstat Therapeutics Corporation
Priority to KR1020217000847A priority patent/KR20210007046A/ko
Priority to CA2898018A priority patent/CA2898018C/en
Priority to BR122021012629-1A priority patent/BR122021012629B1/pt
Publication of WO2014120995A2 publication Critical patent/WO2014120995A2/en
Publication of WO2014120995A3 publication Critical patent/WO2014120995A3/en
Priority to ZA2015/04954A priority patent/ZA201504954B/en
Priority to IL24020515A priority patent/IL240205B/en
Priority to AU2018201239A priority patent/AU2018201239A1/en
Priority to US16/015,264 priority patent/US20180298000A1/en
Priority to US16/285,460 priority patent/US10934284B2/en
Priority to IL269583A priority patent/IL269583B/en
Priority to AU2020200510A priority patent/AU2020200510B2/en
Priority to US17/176,923 priority patent/US12139483B2/en
Priority to US18/906,289 priority patent/US20250034139A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Definitions

  • nucleated eukaryotic cells whether unicellular organisms or constituents of multicellular organism including humans, contain acidified vacuoles that are critical for cellular maintenance and function.
  • these vacuoles comprise lysosomes and other endosomal vesicular organelles.
  • the pH of the interior of lysosomes is typically about 4.5 to 5, maintained by vacuolar ATP-dependent proton pumps and also by Donnan equilibrium effects.
  • Lysosomes contribute to cytosolic pH buffering, protecting the cell from acidic environments, and are also primary sites for degrading and recycling the constituents of aging or damaged organelles such as mitochondria, a process known as autophagy.
  • autophagy There are several important pathological conditions where lysosomal characteristics are altered and contribute to disease pathogenesis, presenting a potential target for pharmacological therapy.
  • a growing body of evidence indicates that a common phenotypic change in invasive cancer cells is a redirection of lysosomes to participate in destruction of surrounding cells via exocytosis of acidic contents, including enzymes.
  • Proteolytic enzymes normally found in lysosomes but secreted by cancer cells, such as cathepsins, can degrade extracellular matrix proteins, facilitating tumor invasion and metastasis.
  • lysosomes and other acidic vacuolar organelles are often enlarged in cancer cells, which aids pH buffering; many solid tumors generate an acidic extracellular environment, favoring invasion, which requires that cancer cells adapt to both produce and tolerate a low extracellular pH.
  • Cancer cells selected in vitro for invasive potential have larger, more acidic lysosomes than do less aggressive cells.
  • Cancer cells exposed to ionizing radiation undergo a protective response involving enlargement and acidification of lysosomes.
  • a related protective response through cancer cells acquire survival advantages is activation of autophagy, which involves fusion of autophago somes containing damamged organelles or other cell debris, with lysosomes; disruption of autophagy can impair cancer cell viability.
  • Some cancer cells also sequester chemotherapy agents in lysosomes, as a mechanism of drug resistance.
  • Chloroquine an antimalarial drug that accumulates in mammalian lysosomes, potentiates, or restores sensitivity to, anticancer activity of several classes of chemotherapy agents and targeted small molecule and antibody cancer treatments.
  • Lysosomotropic fluorescent dyes such as acridine orange can be used to visually differentiate tumors in situ from surrounding tissues, indicating a potential sharp distinction for specific lysosome-targeting cytotoxic agents to selectively kill cancer cells.
  • Lysosomal alterations are also important features of common inflammatory diseases, especially those involving activated macrophages, where exocytosis of lysosomal enzymes, cytokines, and some inflammatory mediators such as HMBG1 that are processed and released via lysosomes can participate in tissue damage and both local and systemic inflammation.
  • Glucocorticoid signaling is also linked to lysosomes, such that compromising lysosomal function can enhance anti-inflammatory pathways mediating glucocorticoid effects.
  • fungi have acidic vacuoles similar to lysosomes. These acidic vacuoles are critical for ion and pH homeostasis, storage of amino acids, autophagy and for processing some proteins. Vacuoles are acidified via a proton pump, the vacuolar H + -ATPase, or "V-ATPase", and it is known that fungi with inactivating mutations of subunits of V-ATPase that result in impaired vacuole acidification also lose virulence and grow poorly.
  • V-ATPase vacuolar H + -ATPase
  • Ergosterol a fungal-specific steroid analogous to cholesterol in mammalian cells as a major membrane component, is critical for conformation and activity of the V-ATPase, and V-ATPase dysfunction appears to be a major mechanism of antifungal activity of ergosterol synthesis inhibitors, which includes several classes of existing antifungal agents.
  • Agents that target fungi via adequately specific targeting and disruption of fungal acidic vacuoles by cation trapping may be less susceptible to development of resistance through point mutations than are drugs acting by binding to specific protein targets, due to impaired viability and virulence when vacuolar acidification, is impaired.
  • Clinically important antimalarial drugs are known that accumulate in acidic vacuoles and lysosomes and their biological activity is largely mediated through their concentration in acidic vacuoles, not only in malaria but in inflammatory diseases, some cancers and non-malarial infections by fungi and unicellular and protozoal parasites.
  • Quinoline analog antimalarial drugs target malaria plasmodia via cation trapping in acidic digestive vacuoles, where they can accumulate to concentrations several orders of magnitude higher than in extracellular spaces.
  • a large molar fraction of chloroquine, mefloquine, quinacrine and several of their congeners are uncharged at the usual extracellular pH of about 7.4 and the cytoplasmic pH of 7.1, and can thereby pass through cellular and organelle membranes.
  • these antimalarials In an acidic environment such as the interior of a lysosome or fungal acidic vacuole, these antimalarials are predominantly cationic and are thereby restricted from free passage through the vacuolar membrane.
  • Antimalarials such as chloroquine impair processing of heme from hemoglobin ingested by malaria plasmodia after accumulating in the feeding vacuoles, accounting for much of their specific toxicity to plasmodia.
  • chloroquine and similar quinoline-analog antimalarials can accumulate in mammalian lysosomes and fungal acidic vacuoles and impair vacuolar function to a degree sufficient to provide some clinical benefit, if only by partically deacidifying the vacuoles.
  • Chloroquine is used for treatment of in chronic autoimmune and inflammatory diseases such as systemic lupus erythematosis or rheumatoid arthritis, with moderate efficacy.
  • a degree of antifungal activity has been reported for antimalarials such as chloroquine or quinacrine, both as single agents or in combination with other classes of antifungal agents, such as fluconazole, notably in animal models of systemic cryptococcosis.
  • antimalarials such as chloroquine or quinacrine
  • other classes of antifungal agents such as fluconazole
  • their activity is suboptimal, yielding incomplete fungal growth inhibition.
  • Recent work has also demonstrated moderate growth inhibitory activity of chloroquine, mefloquine and other weakly cationic drugs such as siramesine in animal models of cancer.
  • lysosomotropic agents such as antimalarial quinolone compounds can thus display some therapeutically relevant activity in diseases in which acidic vacuoles contribute to pathogenesis.
  • the activity and potency of antimalarials in such diseases are limited, as the target cells can tolerate accumulation of relatively high concentrations of the antimalarials; the specific lethal effect of quinoline compounds in malaria is largely attributed to disruption of heme processing within plasmodial feeding vacuoles, a mechanism of cytotoxicity not applicable in the areas of inflammatory disease, cancer or fungal infections.
  • existing agents have not shown adequate activity or therapeutic index for effectively treating cancer in humans.
  • This class of agents accumulate in lysosomes and acidic vacuoles via the same type of cation trapping process through which antimalarials are concentrated, and when they reach a critical micellar concentration in the vacuole, they behave as detergents, damaging vacuolar membranes. They display a characteristic sigmoid dose-response curve, as a consequence of their formation of micellar micro structures.
  • this class of agents in vivo in animal models of relevant diseases.
  • This invention provides a compound represented by Formula I or a pharmaceutically acceptable salt thereof
  • G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms.
  • G can be unsubstituted, or it can substituted at a ring carbon by amino, dimethylamino, hydroxy, halo, methyl, perfluoromethyl, or alkyl having from 1 to 16 carbon atoms which alkyl is either unsubstituted or substituted by hydroxy or alkoxy having 1 to 12 carbon atoms or acetoxy.
  • alkyl having from 1 to 16 carbon atoms which alkyl is either unsubstituted or substituted by hydroxy or alkoxy having 1 to 12 carbon atoms or acetoxy.
  • it can be substituted at a ring nitrogen by alkyl having from 1 to 16 carbon atoms which alkyl is either unsubstituted or substituted by hydroxy or alkoxy having from 1 to 8 carbon atoms.
  • N is nitrogen, H is hydrogen, and NH is absent or present.
  • A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent; Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be O or NH.
  • X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom.
  • Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms.
  • Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(0)R 6 or C(0)NHR 6 or C(0)OR 6 where R 6 is alkyl having from 1 to 6 carbon atoms, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.
  • This invention also provides a use or method for treating or preventing a condition in a mammalian subject; the condition being selected from the group consisting of an inflammatory disease, a fungal infection, a unicellular parasitic infection, and a neoplastic disease; comprising administering to the subject an effective amount of the compound or salt of the invention. It also provides compositions comprising these compounds or salt. And it provides a method of inhibiting a fungus ex vivo, comprising contacting a surface or the fungus with the compound or salt.
  • this invention provides compounds and their use for treating diseases characterized by pathogenic cells featuring lysosomes or other acidic vacuoles with disease-related alterations predisposing them to accumulation of compounds of the invention, which then selectively inactivate or eliminate such pathogenic cells.
  • Compounds of the invention many of which are aminoquinoline and aminoquinazoline derivatives, feature significant improvements in potency and activity over known aminoquinoline drugs such as chloroquine, as a consequence of structural moieties that potently disrupt lysosomal or vacuolar membrane integrity when the compounds accumulate in acidic vacuoles in cells.
  • Diseases that are at least moderately responsive to antimalarial quinoline derivatives and analogs are in general more effectively treated with compounds of the invention.
  • Such diseases broadly comprise inflammatory diseases, neoplastic diseases, including both hematologic cancers and solid tumors, and infections by eukaryotic pathogens, including fungi and several classes of protozoal or other unicellular parasites.
  • alkyl means a linear or branched-chain or cyclic alkyl group.
  • An alkyl group identified as having a certain number of carbon atoms means any alkyl group having the specified number of carbons.
  • an alkyl having three carbon atoms can be propyl or isopropyl; and alkyl having four carbon atoms can be n-butyl, 1-methylpropyl, 2-methylpropyl or t-butyl.
  • halo refers to one or more of fluoro, chloro, bromo, and iodo.
  • perfluoro as in perfluoromethyl, means that the group in question has fluorine atoms in place of all of the hydrogen atoms.
  • variable G means “and/or” unless such reading does not make sense in context. So for example, when it is stated in connection with Formula I that variable G can be substituted at a ring carbon "or” at a ring nitrogen, it may be substituted at a ring carbon, at a ring nitrogen, or at both a ring carbon and a ring nitrogen.
  • G is selected from the group consisting of substituted or unsubstituted quinolyl, substituted or unsubstituted quinazolyl, unsubstituted isoquinolyl, unsubstituted quinoxalyl, unsubstituted benzimidazolyl, unsubstituted pyridyl, unsubstituted pyrazinyl, unsubstituted indolyl, substituted or unsubstituted imidazoquinolyl, substituted pyridinium, unsubstituted imidazopyridine, unsubstituted pyrimidyl, and substituted imidazolyl.
  • A-Q-X-Y-Z is selected from the group consisting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl,
  • alkoxyalkyl alkoxyalkoxyalkyl, phenoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl, N-alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl, isonicotinamidoalkyl, N-(quinolylamino)alkyl, N-(quinazolylamino)alkyl,
  • A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent.
  • Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be O or NH.
  • X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom.
  • Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms.
  • Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(0)R 6 or C(0)NHR 6 or C(0)OR 6 where R 6 is alkyl having from 1 to 6 carbon atoms, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to
  • A-Q-X-Y-Z is selected from the group consisting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl, N-alkylcarbamoylphenyl, alkoxy (halophenyl), phenylalkyl, alkoxy
  • n 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, provided that if p is 1 then n must not be 0 or
  • R 1 and R 2 are hydrogen and the other is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl.
  • R can be alkyl having from 1 to 10 carbon atoms either unsubstituted or substituted by: a) a phenyl or monocyclic or bicyclic aromatic ring having one or two nitrogen atoms or phenoxy either unsubstituted or substituted by phenoxy or alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbon atoms, provided that if R is alkyl substituted by alkoxy then alkyl must have more than 1 carbon atom.
  • R can be phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl or phenoxy, b) alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy, provided that when substituted by phenoxy the alkoxy must have more than one carbon atom, c) phenyl, d) phenoxy, or e) C(0)OR 6 , C(0)NHR 6 , or NHC(0)R 6 , wherein R 6 is alkyl having from 1 to 6 carbon atoms.
  • R 1 is hydrogen and R 2 is hydrogen.
  • n is 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • p is 1; and R is alkyl having from 1 to 6 carbon atoms.
  • Examples of such compounds include N-[8-(Hexyloxy)octyl]quinolin-4- amine, N-(8-Butoxyoctyl)quinolin-4-amine, N-(8-Methoxyoctyl)quinolin-4-amine, N-[6- (Hexyloxy)hexyl]quinolin-4-amine, N-(6-Butoxyhexyl)quinolin-4-amine, N-[10- (Hexyloxy)decyl]quinolin-4-amine, N-(10-Butoxydecyl)quinolin-4-amine, N-(5- Methoxypentyl)quinolin-4- amine .
  • n is 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • p is 1
  • R and R is hydrogen and the other is selected from the group consisting of halo, methyl, and perfluoromethyl; and R is alkyl having from 1 to 6 carbon atoms.
  • examples of such compounds include N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine, 7-Chloro-N-[8- (hexyloxy)octyl]quinolin-4-amine, 8-Chloro-N-[8-(hexyloxy)octyl]quinolin-4-amine, N-[8- (Hexyloxy) octyl] -7 - (trifluoromethyl)quinolin-4- amine, N- [ 8 - (Hexyloxy) octyl] - 8 - (trifluoromethyl)quinolin-4-amine.
  • n 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • p is 1
  • R is alkyl having from 2 to 5 carbon atoms substituted by alkoxy having from 1 to 6 carbon atoms.
  • Examples of such compounds include N- ⁇ 5-[3-(Hexyloxy)propoxy]pentyl ⁇ quinolin-4-amine, N- ⁇ 3-[5-(Hexyloxy)pentyloxy]propyl ⁇ quinolin-4- amine, N- [ 8 - (3 -Ethoxypropoxy) octyl] quinolin-4- amine, N- [ 8 - (2- Propoxyethoxy)octyl]quinolin-4-amine.
  • a subset of compounds of Formula IA1 can be represented by Formula IAla
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8; p is 0 or 1; q is 0 or 1, provided that if p is 1 then n must not be 0 or 1.
  • R 1 and R 2 is hydrogen and the other is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl.
  • R 4 is hydrogen or halo.
  • R 5 is selected from the group consisting of hydrogen; halo; unbranched or branched alkyl having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl or phenoxy; alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy, provided that when substituted by phenoxy the alkoxy must have more than one carbon atom; ; phenyl; phenoxy; C(0)OR 6 ;
  • R 6 is alkyl having from 1 to 6 carbon atoms.
  • R 1 is hydrogen and R 2 is hydrogen.
  • p is 1 and R 4 is hydrogen.
  • R 5 is hydrogen. Examples of such compounds include N-[8-(Benzyloxy)octyl]quinolin-4-amine,
  • both R 1 and R2 are hydrogen, q is 0, and R 5 is alkoxy having from 1 to 6 carbon atoms unsubstituted or substituted by phenyl. In a more specific embodiment R 5 is in the ortho position. Examples of such compounds include
  • Examples of such compounds include N-[8-(3-Methoxyphenoxy)octyl]quinolin-4-amine, N- ⁇ 4- [3-(Hexyloxy)phenoxy]butyl ⁇ quinolin-4-amine, N- ⁇ 3-[3-(Hexyloxy)phenoxy]propyl ⁇ quinolin-4- amine, N- ⁇ 2-[3-(Hexyloxy)phenoxy]ethyl ⁇ quinolin-4-amine.
  • R 5 is in the para position.
  • Examples of such compounds include N-[8-(4-Methoxyphenoxy)octyl]quinolin-4- amine, N-[6-(4-Methoxyphenoxy)hexyl]quinolin-4-amine, N- ⁇ 2-[4-(Hexyloxy)phenoxy]ethyl ⁇ quinolin-4-amine, N- ⁇ 3-[4-(Hexyloxy)phenoxy] propyl ⁇ quinolin-4-amine, N- ⁇ 4-[4- (Hexyloxy)phenoxy] butyl ⁇ quinolin-4-amine .
  • R 1 is hydrogen and R2 is hydrogen, p is 1, R 4 is hydrogen, and R 5 is unbranched or branched alkyl having from 1 to 6 carbon atoms.
  • examples of such compounds include N-[8-(m-Tolyloxy)octyl]quinolin-4-amine, N-[8-(p-Tolyloxy)octyl] quinolin-4-amine, N-[8-(o-Tolyloxy)octyl]quinolin-4-amine, N-[8-(4-ie/ -Butylphenoxy)octyl] quinolin-4- amine.
  • R 5 is fluoro. Examples of such compounds include
  • N- [ 8 - (2-Fluorophenoxy) octyl] quinolin-4-amine R 1 is hydrogen and R 2 is hydrogen, and p is 0. In a more specific embodiment q is 0. In a still more specific embodiment n is 0. Examples of such compound include N-(Biphenyl-4-yl)quinolin-4-amine, N-(4-Hexylphenyl)quinolin-4-amine, Hexyl 4-(quinolin-4-ylamino)benzoate, N-(4-Phenoxyphenyl)quinolin-4-amine,
  • R 5 is alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl.
  • examples of such compounds include N-(4-Methoxyphenyl)quinolin-4-amine,
  • R 1 is hydrogen and R 2 is hydrogen, p is 0, q is 0, and n is 1 or 2.
  • Examples of such compounds include N-Benzylquinolin-4-amine, and
  • R 1 is hydrogen and R 2 is hydrogen, p is 0, and q is 1.
  • R 5 is alkoxy having from 1 to 10 carbon atoms.
  • examples of such compounds include N-[4-(Hexyloxy)benzyl]quinolin-4-amine, N-[3-(Hexyloxy)benzyl]quinolin- 4-amine, N-[2-(Hexyloxy)benzyl]quinolin-4-amine, N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4- amine, N-[4-(Decyloxy)benzyl]quinolin-4-amine, N-[3-(Decyloxy)benzyl]quinolin-4-amine.
  • R 5 is phenoxy, or alkoxy having from 1 to 10 carbon atoms substituted by phenyl.
  • examples of such compounds include N-(3-Phenoxybenzyl)quinolin-4-amine, N-[3-(Benzyloxy)benzyl]quinolin-4-amine, N-(3-Phenethoxybenzyl)quinolin-4-amine.
  • n 2, 3, 4, 5, 6, 7, or 8.
  • R is phenyl unsubstituted or substituted by alkoxy having from
  • R is unsubstituted phenyl.
  • examples of such compounds include N-[4-(Quinolin-4-ylamino)butyl]benzamide,
  • R is phenyl substituted by alkoxy having from 1 to 6 carbon atoms.
  • examples of such compounds include 3-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide, 4-Methoxy-N-[8-(quinolin-4-ylamino)octyl]benzamide, 2-(Hexyloxy)-N-[2-(quinolin-4- ylamino)ethyl]benzamide, 2-(Hexyloxy)-N-[3-(quinolin-4-ylamino)propyl]benzamide,
  • R is 2-pyridyl, 3- pyridyl, or 4-pyridyl.
  • Examples of such compounds include N-[8-(Quinolin-4- ylamino)octyl]picolinamide, N-[8-(Quinolin-4-ylamino)octyl]nicotinamide,
  • compounds of Formula IA include N-(Pyridin-4-ylmethyl)quinolin-4-amine, N-(Pyridin-3-ylmethyl)quinolin-4-amine, N-(Pyridin-2-ylmethyl)quinolin-4-amine, N-Hexylquinolin-4-amine, N-(Decyl)quinolin-4-amine, N-(Dodecyl)quinolin-4-amine,
  • N 1 ,N 8 -Di(quinolin-4-yl)octane-l,8-diamine examples include N-[8-(Hexyloxy)octyl]quinolin-6-amine, N-[8-(Hexyloxy)octyl] quinolin-3-amine, N-[8-(Hexyloxy)octyl]quinolin-8-amine, N-[8-(Hexyloxy)octyl]-2- (trifluoromethyl)quinolin-4-amine, 7-Chloro-N-decylquinolin-4-amine, 7-Chloro-N- dodecylquinolin-4-amine.
  • A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent.
  • Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be O or NH.
  • X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom.
  • Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms.
  • Z is absent or present and is hydrogen, alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, phenyl, phenoxy, or NHC(0)R 6 or C(0)NHR 6 or C(0)OR 6 where R 6 is alkyl having from 1 to 6 carbon atoms, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms.
  • R 1 is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl .
  • R 1 is hydrogen.
  • A-Q-X-Y-Z is selected from the group consisting of alkoxyphenylalkyl, alkoxyphenyl, alkoxyphenoxyalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, phenoxyphenyl, phenoxyphenylalkyl, phenylalkoxyphenylalkyl, phenoxyalkyl, phenylalkoxyalkyl, alkylphenoxyalkyl, alkyl, (halophenoxy)alkyl, biphenyl, alkylphenyl, alkoxycarbonylphenyl, N-alkylcarbamoylphenyl, alkoxy(halophenyl), phenylalkyl, alkoxy(halophenyl)alkyl, (alkoxybenzamido)alkyl, picolinamidoalkyl, nicotinamidoalkyl, isonico
  • a subset of com ounds of Formula IB can be represented by Formula IB l
  • n 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; Q is absent or present and is O or NHC(O), provided that if Q is present n cannot be 0 or 1 ; and provided that if Q is absent, then (CH 2 ) n R
  • R is hydrogen or halo.
  • R is selected from the group consisting of: hydrogen; alkyl having from 1 to 6 carbon atoms; and phenyl or monocyclic aromatic ring having one nitrogen atom, unsubstituted or substituted by alkyl having from 1 to 6 carbon atoms or alkoxy having from 1 to 10 carbon atoms or phenyl or phenoxy.
  • Q is absent.
  • Examples of such compounds include N-(Decyl)quinazolin-4-amine, N-Dodecylquinazolin-4-amine, N-Decyl-7-fluoroquinazolin-4-amine, N-Dodecyl-7- fluoroquinazolin-4-amine, 7-Chloro-N-decylquinazolin-4-amine, 7-Chloro-N-dodecylquinazolin- 4-amine.
  • Q is O or NHC(O).
  • Examples of such compounds include N-(6- Butoxyhexyl)quinazolin-4- amine, N- [ 8 - (Hexyloxy) octyl] quinazolin-4- amine, N-[S- (4-Methoxyphenoxy) octyl] quinazolin-4- amine, N- ⁇ 2- [2- (Hexyloxy)phenoxy] ethyl ⁇ quinazolin-4-amine, N- ⁇ 3-[2-(Hexyloxy)phenoxy]propyl ⁇ quinazolin-4-amine,
  • n is 1
  • Q is absent
  • R is phenyl substituted by alkoxy having from 1 to 10 carbon atoms or phenoxy. Examples of such compounds include N-[3-(Hexyloxy)benzyl]quinazolin-4-amine,
  • imidazoquinolyl can be represented by Formula IC
  • R is hydrogen, OH, NH 2 , or N(CH 3 ) 2 ;
  • R is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl;
  • R is hydrogen, or alkyl having from 1 to 15 carbon atoms unsubstituted or substituted by alkoxy having 1 or 2 carbon atoms or acetoxy;
  • R 9 is a branched or unbranched alkyl having from 1 to 16 carbon atoms, unsubstituted or substituted by hydroxy, or alkoxy having from 1 to 12 carbon atoms, provided that if substituted
  • R is hydrogen.
  • examples of such compounds include l-[2-(Ethoxymethyl)- lH-imidazo[4,5-c]quinolin-l-yl]-2- methylpropan-2-ol, l-(4-Amino-l-isobutyl-lH-imidazo[4,5-c]quinolin-2-yl)pentyl acetate, l-Isobutyl-2-pentadecyl- lH-imidazo[4,5-c]quinolin-4-ol, l-Octyl-lH-imidazo[4,5-c]quinoline, l-Hexadecyl-lH-imidazo[4,5-c]quinoline, l-Hexadecyl- lH-imidazo[4,5-c]quinolin-4-amine, l-Dodecyl- lH-imidazo[4,5-c
  • R 2 is hydrogen
  • R 9 is an unbranched alkyl having from 2 to 10 carbon atoms, substituted by alkoxy having from 1 to 12 carbon atoms.
  • examples of such compounds include l-[2-(Dodecyloxy)ethyl]- lH-imidazo[4,5-c]quinoline,
  • R is alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, provided that if substituted by alkoxy R 10 must have more than 1 carbon atom.
  • R n is hydrogen; or alkyl having from 1 to 8 carbon atoms, unsubstituted or substituted by alkoxy having from 1 to 3 carbon atoms, provided that if substituted by alkoxy R 11 must have more than 1 carbon atom.
  • X " is a counterion.
  • Examples of such compounds include a 4-Amino-l-[8-(hexyloxy)octyl]pyridinium salt, and 4-(8-Methoxyoctylamino)- l- methylpyridinium iodide.
  • G is lH-imidazo[4,5-c]pyridine.
  • R is alkyl having from 2 to 16 carbon atoms, unsubstituted or substituted by alkoxy having from 4 to 6 carbon atoms.
  • examples of such compounds include l-[8-(Hexyloxy)octyl]- lH-imidazo[4,5-c]pyridine, l-Hexadecyl-lH-imidazo[4,5-c]pyridine, 1-(10-Butoxydecyl)-1H- imidazo [4,5 - c] pyridine .
  • G is pyridyl
  • N-(8-Methoxyoctyl)pyridine-4-amine N-[8-(Hexyloxy)octyl]pyridin-3-amine
  • N-[8-(Hexyloxy)octyl]pyridin-2-amine examples include N-(8-Methoxyoctyl)pyridine-4-amine, N-[8-(Hexyloxy)octyl]pyridin-3-amine, and N-[8-(Hexyloxy)octyl]pyridin-2-amine.
  • G examples of this invention in which G is pyrimidyl include N-[8-(Hexyloxy)octyl]pyrimidin-4- amine, and N-[8-Hexyloxy)octyl)pyrimidin-2-amine.
  • G is 5- aryl lH-imidazolyl. Examples of such compounds include l-[8-(Hexyloxy)octyl]-4-phenyl-lH- imidazole.
  • Examples of compounds of this invention in which G is isoquinolyl include N-[8- (Hexyloxy)octyl]isoquinolin-l-amine, N-[8-(Hexyloxy)octyl]isoquinolin-5-amine.
  • Examples of compounds in which G is quinoxalyl include N-[8-(Hexyloxy)octyl]quinoxalin-2-amine.
  • Examples of compounds in which G is benzimidazolyl include l-[8-(Hexyloxy)octyl]-lH- benzimidazole.
  • Examples of compounds in which G is pyrazinyl include N-[8-
  • (Hexyloxy)octyl]pyrazin-2- amine examples include l-[8- (Hexyloxy)octyl]-lH- indole.
  • G is 3H-imidazo[4,5- b]pyridine.
  • examples of such compounds include 3-[8-(Hexyloxy)octyl]-3H-imidazo[4,5- b]pyridine.
  • one or more of the following compounds are excluded: imiquimod; 4-(n-decylamino)quinoline [58911-14-1]; 4-decylaminoquinazoline [22754-12-7].
  • the compound in substantially (at least 98%) pure form.
  • This invention provides prodrugs of the compounds and salts described above, and their uses as described herein. Whenever a phenyl ring is substituted, the substitution may be at the ortho-, meta-, or para-position.
  • the compounds of the present invention can be made in accordance with the following reaction schemes.
  • G is a monocyclic or bicyclic aromatic ring having one or two ring nitrogen atoms, either unsubstituted or substituted at a ring carbon by halo, methyl, or perfluoromethyl;
  • N nitrogen
  • H hydrogen
  • A is absent or present and is alkyl having from 1 to 12 carbon atoms, provided that if A has 1 carbon atom Q must be absent;
  • Q is absent or present and is O, NHC(O), or NH, provided that if A is absent Q must be absent, and if both X and Y are absent Q cannot be O or NH;
  • X is absent or present and is alkyl having from 1 to 5 carbon atoms, provided that if Y is absent and Z is alkoxy or phenoxy X must have more than 1 carbon atom;
  • Y is absent or present and is phenyl unsubstituted or substituted by halo, or is a monocyclic or bicyclic aromatic ring having one nitrogen atom;
  • Z is absent or present and is: a) hydrogen, b) alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, c) alkoxy having from 1 to 10 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, d) phenyl, e) phenoxy, or f) NHC(0)R 6 or C(0)NHR 6 or C(0)OR 6 where R 6 is alkyl with 1 to 6 carbon atoms except if both X and Y are absent, provided that if all of A, Q, X, and Y are absent then Z must be alkyl having 6 to 12 carbon atoms, can be prepared from the reaction of the compound of formula 1 with the compound of formula 2 where LG is a leaving group such as a halogen, a sulfonyloxy, a siloxy, or a borate via the reaction scheme in Scheme 1.
  • step (a) can proceed thermally without the use of a catalyst, and LG is halo is preferred, and LG is chloro is most preferred.
  • G is preferably selected from the group of compounds consisting of unsubstituted or substituted 4-quinolyl, 4-quinazolyl, 2-quinolyl, 2-quinazolyl, 1-isoquinolyl, 3-isoquinolyl, 2- quinoxalyl, 1-phthalazyl, 2-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, and 2-pyrazinyl.
  • the compound of formula 1 and the compound of formula 2 and a suitable base such as
  • triethylamine, tripropylamine, N-methylmorpholine, or diisopropylethylamine are heated in a suitable solvent such as 1-pentanol, 1-butanol, 2-propanol, dimethylformamide, N- methylpyrrolidinone, or a mixture of suitable solvents.
  • a suitable solvent such as 1-pentanol, 1-butanol, 2-propanol, dimethylformamide, N- methylpyrrolidinone, or a mixture of suitable solvents.
  • a catalyst such as a transition metal complex catalyst such as a palladium complex or a nickel complex.
  • T CH and R is present or T is N and R is absent and where either: a) n is 2-12 and p is 1 ; or b) n is 0 or 1 and p is 0; and where q is 0 or 1, and one of
  • R and R is hydrogen and the other is selected from the group consisting of hydrogen, halo, methyl, and perfluoromethyl, and R is alkyl having from 1 to 10 carbon atoms either unsubstituted or substituted by: a) a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms or phenyl either unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbons, provided that if R is alkyl substituted by alkoxy then alkyl cannot have 1 carbon atom; phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy provided that when substituted by phenoxy the alkoxy must have more than one carbon atom, c
  • the compound of formula 3 is reacted with the compound of formula 4 to give the compound of formula 5 via reaction of step (a): the compound of formula 3 is treated with a suitable base and then is reacted with the compound of formula 4.
  • the selectivity of the reaction for substitution of only one of the bromides of the compound of formula 4 can be increased by using a stoichiometric excess of the compound of formula 3.
  • n is 1, any base that is commonly used to convert an alcohol to an alkoxide is suitable, such as sodium hydride or a hindered alkali metal alkoxide such as sodium isopropoxide.
  • n 1, the base must be completely reacted with the compound of formula 3 before the addition of the compound of formula 4 is performed. If n is 0, any base that is commonly used to convert a phenol to a phenoxide is suitable, such as potassium carbonate or sodium carbonate. If n is 0, the compound of formula 4 may be present when the base is reacted with the compound of formula 3.
  • the compound of formula 5 is converted to the compound of formula 6 via reactions of step (b), the Gabriel synthesis of primary amines.
  • the compound of formula 5 is reacted with potassium phthalimide under conventionally used conditions to give the phthalimide
  • the compound of formula 6 is converted to the compound of formula 7 via step (c): the compound of formula 6 reacts with the compound of formula 7 in the presence of a tertiary amine base such as triethylamine, diisopropylethylamine, or tripropylamine at elevated temperature in a suitable solvent, such as 2-propanol heated at reflux if T is N or 1-pentanol heated at reflux or dimethylformamide or N-methylpyrrolidinone at 130-150 °C if T is CH.
  • a tertiary amine base such as triethylamine, diisopropylethylamine, or tripropylamine at elevated temperature in a suitable solvent, such as 2-propanol heated at reflux if T is N or 1-pentanol heated at reflux or dimethylformamide or N-methylpyrrolidinone at 130-150 °C if T is CH.
  • step (a) The compound of formula 3 where q is 0 or 1 and R is alkyl having from 1 to 10 carbon atoms substituted by alkoxy having from 1 to 12 carbon atoms, provided that if R is alkyl substituted by alkoxy then alkyl cannot have one carbon, can be prepared via the reaction scheme in Scheme 3.
  • step (a) the compound of formula 9 where n is 2-11 is treated with any base that is commonly used to convert an alcohol to an alkoxide, such as sodium hydride or a hindered alkali metal alkoxide such as sodium isopropoxide.
  • the compound of formula 10 where R 6 is alkyl having from 1 to 12 carbon atoms is added.
  • the selectivity of the reaction for alkylation of only one of the hydroxyls of the compound of formula 9 can be increased by using a stoichiometric excess of the compound of formula 9.
  • the compound of formula 3 where q is 0 or 1 and R is phenyl substituted by halo, alkoxy having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy can be prepared from the compound of formula 11 where q is 0 or 1 and R 4 is hydrogen or halo via the reaction scheme in Scheme 4.
  • the compound of formula 11 is treated with a suitable base such as potassium carbonate or sodium carbonate and reacted with the compound of formula 10, where R 6 is alkyl having from 1 to 10 carbon atoms unsubstituted or substituted by phenyl or phenoxy.
  • the compound of formula 6 where n is 0, p is 0, q is 0, and R is phenyl unsubstituted or substituted by halo, C(0)OR 6 wherein R 6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the compound of formula 12 where R 4 is hydrogen or halo and the compound of formula 13 where R 6 is alkyl having from 1 to 6 carbon atoms via the reaction scheme in Scheme 5.
  • the compound of formula 12 may be commercially available or can be prepared from the carboxylic acid using conventional methods.
  • the compound of formula 14 where R 4 is hydrogen or halo and R 5 is C(0)OR 6 wherein R 6 is alkyl having from 1 to 6 carbon atoms is prepared from the reaction of the compound of formula 12 with the compound of formula 13 in the presence of a base such as pyridine or triethylamine via step (a). Any of the conventional methods for the preparation of carboxylic esters from carboxylic acids or their derivatives and alcohols may be used to prepare the compound of formula 14. If the compound of formula 13 is replaced by the amine analog, the reaction scheme will produce the compound of formula 6 where R 3 is substituted by C(0)NHR 6 .
  • the compound of formula 14 is reduced to form the compound of formula 6 by catalytic reduction using hydrogen and a palladium on charcoal catalyst via step (b). Any of the conventional methods for selective reduction of nitro groups to amino groups in the presence of carboxylic ester groups can be used in step (b).
  • the compound of formula 6 where n is 0, p is 0, q is 0, and R is phenyl unsubstituted or substituted by halo, NHC(0)R 6 wherein R 6 is alkyl having from 1 to 6 carbon atoms can be prepared starting from the compound of formula 15 where R 4 is hydrogen or halo and the compound of formula 16 where R 6 is alkyl having from 1 to 6 carbon atoms via the reaction scheme in Scheme 5.
  • the compound of formula 15 and the compound of formula 16 can react to produce the compound of formula 14 where R 4 is hydrogen or halo and R 5 is NHC(0)R 6 wherein R 6 is alkyl having from 1 to 6 carbon atoms via the reaction of step (a) under any conventional conditions for preparing carboxamides from the reaction of amines with carboxylic acid chlorides.
  • the compound of formula 14 is reduced to form the compound of formula 6 by catalytic reduction using hydrogen and a palladium on charcoal catalyst via step (b). Any of the conventional methods for reduction of nitro groups to amino groups can be used in step (b).
  • the compound of formula 6 where n is 0, p is 0, q is 0, and R is phenyl unsubstituted or substituted by halo, alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group, can be prepared starting from the compound of formula 17 where R 4 is hydrogen or halo and the compound of formula 10 where R 6 is alkyl having from 1 to 12 carbon atoms either unsubstituted or substituted by phenyl or phenoxy via the reaction scheme in Scheme 7.
  • a mixture of compound of formula 17 and compound of formula 10 is reacted in the presence of a suitable base such as potassium carbonate or sodium carbonate and a suitable solvent such as dimethylformamide to give compound of formula 14 where R 4 is hydrogen or halo and R 5 is alkoxy having from 1 to 12 carbon atoms either unsubstituted or substituted by one phenyl or phenoxy group.
  • the compound of formula 14 is reduced to form the compound of formula 6 by catalytic reduction using hydrogen and a palladium on charcoal catalyst via step (b). Any of the conventional methods for reduction of nitro groups to amino groups can be used in step (b).
  • Scheme 7 Any of the conventional methods for reduction of nitro groups to amino groups can be used in step (b).
  • the compound of formula 3 is converted to the compound of formula 18 via the reaction of step (a) by treatment with thionyl chloride. Any of the reagents and reactions that are used conventionally to convert an alcohol and particularly a benzylic alcohol to a halide and particularly a benzylic halide can be used in step (a). Alternatively, the compound of formula 3 is converted to the compound of formula 19 via the reaction of step (b) by treatment with methanesulfonyl chloride and triethylamine.
  • step (b) any sulfonylation reagent that is conventionally used to convert a hydroxyl to a leaving group can be substituted for methanesulfonyl chloride, and any suitable base can be used in place of triethylamine.
  • the compound of formula 18 or the compound of formula 19 is converted to the compound of formula 6 via reactions of step (c), the Gabriel synthesis of primary amines.
  • the compound of formula 18 or the compound of formula 19 is reacted with potassium phthalimide under conventionally used conditions to give the phthalimide intermediate, which is converted to the compound of formula 6 under conventionally used conditions such as hydrazine
  • the compound of formula 20 is reacted with the compound of formula 10 where R 6 is alkyl having from 1 to 6 carbon atoms in the presence of a suitable base such as potassium carbonate via the reaction of step (a).
  • a suitable base such as potassium carbonate
  • the benzoic acid derivative of the compound of formula 20 can be used as the starting material, as well, if two equivalents of the compound of formula 10 and two equivalents of a suitable base are used.
  • the compound of formula 21 can be reacted with the compound of formula 22 where n is 2-8 to produce the compound of formula 23 via the reaction of step (b).
  • Step (b) can be carried out in the absence of solvent at a temperature of 100-130 °C.
  • the selectivity of acylation of only one of the amino groups of the compound of formula 22 can be increased by using a stoichiometric excess of the compound of formula 22.
  • the compound of formula 23 can be reacted with the compound of formula 8 to give the compound of formula 24 via the reaction of step (c).
  • a mixture of the compound of formula 23 and the compound of formula 7 where T is CH and R 1 and R 2 are hydrogen is heated inl-pentanol at reflux or dimethylforaiamide or N-methylpyrrolidinone or a mixture thereof at 130-160 °C in the presence of a suitable base such as triethylamine, tripropylamine, N-methylmorpholine, or
  • Step (d) is performed using the same solvent, temperature, and base as described for step (c).
  • the compound of formula 21 can be converted to the compound of formula 26 via the reactions of step (e).
  • Any conventional method for the conversion of a carboxylic ester to a carboxylic acid chloride can be used for step (e); e.g., basic saponification and then reaction with thionyl chloride, oxalyl chloride, phosphoryl chloride, or phosphorus(V) chloride.
  • AQXYZ is represented by R 8
  • R 9 is a branched or unbranched alkyl having from 1 to 16 carbon atoms, unsubstituted or substituted by hydroxy or alkoxy having from 1 to 12 carbon atoms, provided that if substituted by hydroxy or alkoxy R 9 cannot have 1 carbon atom
  • AQXYZ is represented by R 9
  • R 8 is hydrogen or alkyl having from 1 to 15 carbon atoms unsubstituted or substituted by alkoxy having 1 or 2 carbon atoms or acetoxy can be prepared starting from the compound of formula 27 where R 1 is hydrogen or hydroxy and R is hydrogen, halo, methyl, or perfluoromethyl via the reaction scheme in Scheme 10.
  • step (a) compound of the formula 27 where R 1 is hydrogen or hydroxy is nitrated to produce the compound of the formula 28 using nitric acid in hot acetic acid or propionic acid.
  • step (b) the compound of formula 28 is treated with a chlorinating agent such as phosphoryl chloride, alone or in combination with phosphorus(V) chloride, or with phenylphosphonic dichloride to produce the compound of formula 29, where R 1 is chloro if the compound of formula 28 had hydroxy as R 1 .
  • step (c) the compound of formula 29 is reacted with the compound of formula 30 in the presence of a tertiary amine base such as triethylamine in an inert solvent such as
  • step (c) the 4-chloro of the compound of formula 29 where R 1 is chloro is the more reactive with amines. Any of the amines described in the invention can be used in step (c). It was discovered that if compound of formula 29 where R 1 is chloro is stirred with the compound of formula 30 in a mixture of dimethylformamide and dichloromethane initially, and then the dichloromethane is replaced with toluene and the mixture is heated at reflux, the compound of formula 31 where R 1 is N(CH 3 ) 2 is produced. In step (d), the nitro group of the compound of formula 31 is reduced by any of a number of methods.
  • step (e) the ortho-diamine of the compound of formula 32 is heated with the carboxylic acid compound of formula 33 or the compound of formula 34, the ortho ester of the compound of 33, to produce the compound of formula 35. Any ortho ester analog of the compound of formula 33 may be used.
  • step (f) if the compound of formula 35 where R 1 is chloro is treated with hydrolytic conditions, the compound of formula 36 where R 1 is hydroxy is produced. In step (f), if the compound of formula 35 where R 1 is chloro is treated with ammonia or a primary amine, the R ⁇ amino derivative of the compound of formula 36 is produced. In step (f), if the compound of formula 35 where R 1 is chloro is treated with zinc dust and hydrochloric acid, the compound of formula 36 where R 1 is hydrogen is produced.
  • the compound of formula 35 where R 1 and R2 and R 8 are hydrogen and R 9 is stable to organolithium bases can be reacted with an organolithium base and then alkylated by an organohalide or aldehyde to give the compound of formula 36 where R contains the derivative of the alkylation reagent.
  • R is selected from the group consisting of: alkyl having from 1 to 10 carbon atoms either unsubstituted or substituted by: a) a monocyclic or bicyclic aromatic ring having one or two nitrogen atoms either unsubstituted or substituted by alkoxy having from 1 to 6 carbon atoms, or b) alkoxy having from 1 to 6 carbon atoms, provided that if R is alkyl substituted by alkoxy then alkyl must have more than 1 carbon atom; and phenyl unsubstituted or substituted by halo and unsubstituted or substituted by: a) alkyl having from 1 to 6 carbon atoms, b) alkoxy having from 1 to 10 carbon atoms unsub
  • step (a) the compound of formula 5 is reacted with the alkali metal salt of acetic acid, such as potassium acetate or sodium acetate or lithium acetate, in a suitable solvent such as dimethylformamide. Then, the acetate ester is hydrolyzed at moderately basic pH to produce the compound of formula 37.
  • the compound of formula 37 a primary alcohol, can be oxidized to the carboxylic acid compound of the formula 33 via the reaction of step (b) using any of the numerous suitable methods for the oxidation of alcohols to acids, such as the Jones oxidation.
  • step (d) the compound of formula 38 is treated with an alcohol such as methanol and an acid catalyst such as hydrochloric acid to form the compound of formula 34.
  • Compound 39 is heated at 130-140 °C in a hindered alcohol such as 2-propanol in the presence of a tertiary amine base such as triethylamine with the compound of formula 40 to give the compound of formula 41.
  • a hindered alcohol such as 2-propanol
  • a tertiary amine base such as triethylamine
  • the compound of formula 41 is reacted with an alkyl sulfonate such as the compound of formula 42 in a suitable solvent such as acetone to give the compound of formula ID, where X " is a counterion such as methanesulfonate, iodide, bromide, or chloride.
  • Any alkyl iodide or alkyl bromide or alkyl sulfonate derivative of R 10 can be used in the reaction of step (b). cheme 12.
  • the compound of formula 48 where R is alkyl having from 2 to 16 carbon atoms, unsubstituted or substituted by alkoxy having from 4 to 6 carbons, can be prepared starting from compound 43, 4-hydroxy-3-nitropyridine, by the scheme shown in Scheme 13.
  • Compound 43 is reacted with a suitable halogenating agent such as phenylphosphonic dichloride to give compound 44, 4-chloro-3-nitropyridine via the reaction of step (a).
  • Compound 44 is reacted with the compound of formula 45 in the presence of a suitable base such as triethylamine in a suitable solvent such as pyridine to produce the compound of formula 46 via the reaction of step (b).
  • a suitable base such as triethylamine
  • a suitable solvent such as pyridine
  • the nitro group of the compound of formula 46 is reduced to the amino group of the compound of formula 47 by catalytic hydrogenation via the reaction of step (c).
  • the compound of formula 47 is heated in triethyl orthoformate to produce the compound of formula 48 via the reaction of step (d).
  • the compound of formula 52 is prepared.
  • Any compound of formula 53 where G is a monocyclic, bicyclic, or tricyclic aromatic ring having one, two, or three ring nitrogen atoms where a ring nitrogen atom is bonded to hydrogen can react with the compound of formula 55 where Br-AQXYZ is a primary alkyl bromide to produce the compound of the formula 54, where AQXYZ is given by claim 1 for the compound of formula I, by the scheme shown in Scheme 14.
  • the compound of the formula 53 is treated with a strong base such as sodium ie/ -butoxide in a suitable solvent such as dimethylformamide, and the resulting amide anion is treated with the compound of formula 55 to produce the compound of formula 54 via the reaction of step (a).
  • the alkylation by the compound of formula 55 occurs at the less hindered nitrogen selectively.
  • the primary alkyl iodide, chloride, alkanesulfonate, or arylsulfonate of AQXYZ can be used in place of the compound of formula 55 for the reaction of step (a).
  • the compound of the formula 56 where the radical (AQXYZ) is terminated by a primary alcohol function and where (AQXYZ) does not contain another alcohol group or an amino group, can undergo oxidation by any of a variety of conventional methods such as the Swern oxidation or oxidation by tetrapropylammonium perruthenate/N-methylmorpholine N-oxide to produce the compound of formula 57 via the reaction of step (a).
  • the compound of formula 58 can undergo reductive alkylation by the compound of formula 57 via the reaction of step (b) using any conventional method for amine reductive alkylation such as by sodium
  • step (d) can undergo acylation by the carboxylic acid radical of (AQXYZ) via the reaction of step (d) using any conventional method for amide formation such as a carbodiimide condensation or a mixed anhydride acylation using isopropyl chloroformate.
  • step (d) can be carried out using the acid chloride derivative of the compound of formula 60, which can be produced using any conventional reagent for the preparation of acid chlorides such as thionyl chloride or oxalyl chloride.
  • the compound of formula 60 can be produced from the compound of formula 56 via the reaction of step (c) using any suitable conventional reagent for the oxidation of alcohols such as the Jones reagent.
  • the amide group of the compound of formula 61, where (AQXYZ) does not contain an ester or another amide group, can be reduced to the amino group of the compound of formula 59 via the reaction of step (e) using a suitable reducing agent such as lithium aluminum hydride.
  • the compound of the formula 56 where the radical (AQXYZ) is terminated by a primary alcohol function and where (AQXYZ) does not contain another alcohol or amino group, can undergo a sulfonylation reaction using methanesulfonyl chloride and an amine base such as pyridine or triethylamine to produce the compound of formula 62 via the reaction of step (a).
  • the compound of formula 58 can undergo substitutive alkylation by the compound of formula 62 to produce the compound of formula 59 via the reaction of step (b) using any conventional method for amine alkylation, such as heating the mixture in tetrahydrofuran or dimethylformamide in the absence or presence of a base such as triethylamine, diisopropylamine, or N-methylmorpholine.
  • a base such as triethylamine, diisopropylamine, or N-methylmorpholine.
  • Analogs of the compound of formula 62 where the methanesulfonate group is replaced by a conventional good leaving group such as iodide, bromide, chloride, or a different sulfonate group can be used in step (b).
  • This invention provides certain compounds, described below, for treating diseases characterized by pathogenic cells featuring lysosomes or other acidic vacuoles with disease-related alterations predisposing them to accumulation of compounds of the invention, which then selectively inactivate or eliminate such pathogenic cells.
  • Compounds of the invention many of which are aminoquinoline and aminoquinazoline derivatives, feature significant improvements in potency and activity over known aminoquinoline drugs such as chloroquine, as a consequence of structural moieties that potently disrupt lysosomal or vacuolar membrane integrity when the compounds accumulate in acidic vacuoles in cells.
  • Diseases that are at least moderately responsive to antimalarial quinoline derivatives and analogs are in general more effectively treated with compounds of the invention.
  • Such diseases broadly comprise inflammatory diseases, neoplastic diseases, including both hematologic cancers and solid tumors, and infections by eukaryotic pathogens, including fungi and several classes of protozoal or other unicellular parasites.
  • compositions containing a compound of this invention as well as the use of a compound of this invention for the manufacture of a medicament for treatment or prevention of inflammatory diseases.
  • Compounds of the invention display selectivity for suppressing or inactivating macrophages that have been stimulated into a pro-inflammatory state, with less of an effect on non- stimulated macrophages. Activated pro-inflammatory macrophages contribute to pathogenesis of a large variety of inflammatory and autoimmune diseases.
  • Macrophages are both antigen presenting cells and effectors for tissue damage directed by autoreactive T cells, and participate in tissue damage and dysfunction in diseases including but not limited to rheumatoid arthritis, systemic lupus erythematosis, psoriasis, inflammatory bowel disease, and atopic dermatitis.
  • Inflammatory macrophages participate in many systemic diseases, including autoimmune diseases, cardiovascular and metabolic diseases, and
  • Activated macrophages play a primary role in tissue damage in instability of atherosclerotic plaques, with consequent risk of rupture and thrombotic vessel occlusion.
  • Activated macrophages in adipose tissue contribute to metabolic abnormalities including insulin resistance, type 2 diabetes and other consequences of obesity.
  • Osteoclasts are macrophage-like cells that mediate bone degeneration in osteoporosis and in participate in bone destruction and "bone pain" in cancers arising in or metastasized to bones. Compositions of the invention are useful for treating these and other disorders in which activated macrophages contribute to inflammatory disease pathogenesis.
  • topical agents are used for treatment of inflammatory diseases of the skin, such as atopic dermatitis, eczema or psoriasis.
  • Corticosteroids are widely used, but have the potential for both local and systemic toxicities, particularly with prolonged use. They can cause local skin atrophy or thinning, which may lead to disruption of the skin, as well as telangiectasia.
  • topical corticosteroids can be absorbed systemically in amounts sufficient to cause systemic side effects.
  • a second class of agents for treatment of atopic dermatitis is T cell immunosuppressants, such as the calcineurin inhibitors tacrolimus and pimecrolimus. Their local and systemic immunosuppressive effects have led to concerns about depressing
  • Vitamin D analogs notably calcipotriene, are known for topical treatment of psoriasis.
  • Calciptoriene acts by inhibiting excessive proliferation of keratinocytes.
  • Application to normal skin is contra-indicated due to a bleaching effect and there is also a possibility of adverse events from systemic absorption. Dermal irritation or itching is known as a side effect of calcipotriene.
  • Compounds of the invention are particularly active against macrophage precursors that have been activated by exposure to vitamin D3. It is possible that psoriasis treatment with
  • calcipotriene while providing some improvements by inhibiting keratinocyte proliferation, may also direct local macrophages toward a pro-inflammatory state, contributing to known side effects such as irritation, and limiting the net therapeutic effect.
  • the ability of compounds of the invention to inactivate pro-inflammatory vitamin D3-primed macrophage precursors as shown in several Examples below indicates that combination topical treatment with compounds of the invention and vitamin D analogs may provide unexpected benefits in psoriasis and psoriatic dermatitis, both in treating the inflammatory epidermal hyperproliferation and in reducing irritation or itching as side effects of vitamin D analogs.
  • Compounds of the invention are useful for treating ocular inflammation, including keratitis, whether caused by infection (fungal, bacterial, amoebic) or by non-infectious triggers such as corneal injury or contact lenses.
  • Compounds of the invention are especially suitable for fungal keratitis, counteracting both infectious fungi and concurrent inflammatory damage.
  • Compounds of the invention inhibit corneal angiogenesis and other inflammatory changes in response to mechanical or chemical injury.
  • Impetigo is a superficial bacterial skin infection with inflammatory damage to the epidermia; compounds of the invention both suppress inflammation and have direct inhibitory or bactericidal effects on gram positive bacteria, including but not limited to Staphylococcus aureus and Staphylococcus pyogenes, the primary organisms responsible for impetigo.
  • Compounds of the invention also inhibit pre-neoplastic and neoplastic skin alterations, which often exhibit characteristics of both inflammation and neoplasia, including but not limited to actinic keratosis, seborrheic keratoses and warts.
  • Examples E and F demonstrate efficacy of compounds of the invention for treating skin inflammation and psoriatic dermatitis in established mouse models of human skin disorders.
  • Macrophages and related cells types contribute to pathogenesis of autoimmune diseases involving the adaptive immune system both as antigen presenting cells and as effectors damaging tissues after inappropriate stimulation by T cells, which secrete interferon gamma and other inflammatory mediators that recruit and activate macrophages.
  • Compounds of the invention disrupt antigen presentation by macrophages and dendritic cells, and also inactivate pro-inflammatory effector macrophages that damage tissues.
  • a general guidance is that compounds of the invention are useful for treating chronic or episodic autoimmune diseases where chloroquine, hydroxychloroquine or other antimalarial quinoline analogs display activity in humans or relevant animal models, and are generally more potent and active than the antimalarials in inflammatory and non-malaria infectious diseases.
  • Such diseases include but are not limited to rheumatoid arthritis, systemic and discoid lupus erythematosis, psoriatic arthritis, vasculitis, Sjogrens syndrome, scleroderma, autoimmune hepatitis, and multiple sclerosis.
  • Macrophage activation syndrome is an acute complication of several autoimmune diseases, especially in childhood-onset conditions such as idiopathic juvenile arthritis where it affects more than 10% of patients, and also in inflammatory bowel diseases.
  • MAS Macrophage activation syndrome
  • macrophages are over- activated, causing damage to the hematopoietic system and systemic inflammation; MAS is sometimes lethal.
  • Compounds of the invention are useful for treatment of MAS, and are optionally delivered orally or by intravenous injection or infusion.
  • Example G shows beneficial activity of compounds of the invention when administered orally to mice in a model of multiple sclerosis, an autoimmune disease.
  • compounds of the invention are administered systemically, preferably orally.
  • intravenous treatment with compounds of the invention is an optional suitable delivery route.
  • compounds of the invention are typically administered in doses ranging from 1 to 1000 milligrams per day, advantageously 100 to 600 milligrams per day, in single doses or divided into two or three doses per day.
  • the compounds of this invention are useful in inhibiting fungal growth, both in vivo and ex vivo. Accordingly this invention also provides methods and uses for inhibiting the growth of a fungus in a mammalian subject, for example a human. These methods can be used to treat and to prevent fungal infection. Ex vivo, it is useful to treat surfaces with a compound of this invention to inhibit or prevent fungal growth, or in agriculture or horticulture to prevent or treat fungi that affect valuable plants. This invention also provides compositions containing a compound of this invention as well as the use of a compound of this invention for the manufacture of a
  • This invention is based, in part, on the finding that the compounds of this invention are effective in inhibiting the growth of a variety of fungal species, as shown in the biological activity examples below. Without wishing to be bound by theory, it is believed that compounds of this disclosure exploit the vulnerability of the fungal acidic vacuole. They are believed to accumulate in acidic vacuoles via cation trapping, and furthermore exert antifungal activity by disrupting the structure and function of the acidic vacuoles.
  • the growth of fungi generally is inhibited.
  • fungi that can be inhibited include but are not limited to Candida, Saccharomyces, Trichophyton, Cryptococcus, Aspergillus, and Rhizopus.
  • the fungus is Candida albicans; Candida glabrata; Saccharomyces cerevisiae ; Trichophyton rubrum; Cryptococcus neoformans, for example Cryptococcus neoformans serotypes D and A; and Aspergillus fumigatus.
  • This invention also provides methods of treating and preventing parasitic infections. Due to the capability of compounds of the invention to enter and accumulate within acidic vacuoles in cells, they are useful for treating infections due to parasitic microorganisms that reside within acidic vacuoles in macrophages and other ceil types. Tuberculosis (mycobacteria), listeria or staphylococcus (gram positive bacteria), cryptococcus (fungus), and leishmania and
  • trypanosomes amoebae
  • Coxiella burnetii gram negative bacteria
  • Plasmodium some of which cause malaria
  • Parasites whose viability or virulence is dependent on integrity and function of an acidic vacuole are also vulnerable to compounds of the invention, similar to the basis for their antifungal activity.
  • the acidic vacuole of malaria plasmodia provides an environment for concentration of compounds of the invention.
  • trypanosomes have a large acidic vacuole which is necessary for utilization of environmental nutrients.
  • Compounds of the invention are useful for treatment or prevention of malaria and trypanosome infections. More broadly, protozoal parasites in general use acidified digestive vacuoles for acquisition and digestion of food, and are therefore susceptible to antiparasitic actions of compounds of the invention.
  • chloroquine acts by accumulating in acidic vacuoles via cation trapping.
  • Activity of chloroquine is thus an indicator of likely activity of compounds of the inventions (many of which comprise an aminoquinoline or other heterocycle similar to that of chloroquine for the purpose of targeting acidic vacuoles), with the difference that compounds of the invention are substantially more potent and active than is chloroquine, as demonstrated in Cryptococcus neoformans in Example K, where chloroquine produced less than 50% growth inhibition at a concentration of 100 micromolar, whereas many compounds of the invention produced 100% growth inhibition at much lower concentrations.
  • Chloroquine despite published reports showing that it can improve survival in animal models of cryptococcosis, displays a ceiling of about 40% inhibition of C. neoformans growth in vitro, whereas compounds of the invention are substantially more potent than chloroquine and can cause 100% inhibition of Cryptococcus growth, due to superior disruption of the membranes of acidic vacuoles in which the respective drugs are accumulated.
  • compounds of the invention are administered in vehicles and by routes of administration appropriate for the nature and location of the infection.
  • compound of the invention are applied in a topical formulation which is optionally a lotion, ointment, solution, suspension, or spray.
  • a topical formulation which is optionally a lotion, ointment, solution, suspension, or spray.
  • compounds of the invention are formulated in eyedrops.
  • compounds of the invention are administered orally in tablets, capsules, dragees, solutions or suspensions, or administered systemicaliy by injection in saline, lipid emulsions, liposomes or other standard parenteral vehicles.
  • Lung infections especially involving organisms residing in alveolar macrophages, are optionally treated via inhaiationai delivery of compounds of the invention and suitable excipients known to be acceptable for inhaiationai drug delivery.
  • compounds of the invention are administered in doses ranging from 10 to 2000 milligrams per day, advantageously 200 to 1000 milligrams per day.
  • antifungal agents in clinical use include inhibitors of ergosterol synthesis ("azole” antifungals including but not limited to fluconazole, ketoconazole, voriconazole, and allylamines including but not limited to terbinafine), polyene antifungals which act by binding to fungal membrane constituents, especially ergosterol (including but not limited to amphotericin B or nystatin), echinocandin inhibtors of gluoan synthesis (including but not limited to
  • caspofungin and other agents known as active antifungals in medical practice.
  • Compounds of the invention act via a distinct mechanism of action versus existing clinically important antifungals and are optionally coadministered with one or more other antifungal agent to improve overall antifungal treatment.
  • Compounds of the invention are coadministered as separate pharmaceutical formulations, or are optionally formulated into a single combined-drug product.
  • a combination of compounds of the inventions with azole antifungals is particularly advantageous as a completely oral regimen for use against cyptoccoccosis, which otherwise generally requires amphotericin B injections or infusions for intial induction.
  • Compounds of the invention are also optionally coadministered with amphotericin B.
  • amphotericin B involves its incorporation into lipids comprising the membranes of liposomes. Because many of the compounds of the invention bear lipophilic moieties that insert into lipid membranes, they are advantageously incorporated into liposomes, either as single agents or in combination with amphotericin B or other known polyene antifungal agents.
  • This invention provides compounds that are useful for systemic treatment of cancer, based on consistent lysosomal changes characterizing invasive cancers.
  • Lysosomal changes in cancer including their enlargement and acidification, facilitates survival of cancer cells in acidic extracellular environments and also increase the ability of cancer cells to invade surrounding tissues, through exocytosis of lysosomal contents, including proteases and polysaccharidases which can degrade extracellular matrix components.
  • these stereotyped changes in lysosomal properties can render cancer cells vulnerable to lysosome-disrupting agents with appropriate physicochemical properties for selectively accumulating in and damaging lysosomes in cancer cells versus normal tissues.
  • Compounds of the invention accumulate in lysosomes in cancer cells and disrupt their integrity, thereby displaying potent selective cytotoxic activity against cancer cells in vivo and in vitro. Because one major mechanism for cancer cell resistance to a variety of chemotherapy agents is to sequester them in lysosomes and other acidic vesicular compartments, compounds of the invention are able to restore or enhance sensitivity of cancer cells to a variety of classes of anticancer agents, including antimetabolites, tyrosine kinase inhibitors, anticancer antibodies against growth factor receptors, anthracyclines, platinum compounds, alkylating agents, and antibodies. Compounds of the invention typically do not display toxicities overlapping dose limiting toxicities of most anticancer agents, permitting combination of compounds of the invention with other classes of antineoplastic drugs with a net improvement in efficacy and therapeutic index.
  • Cancer cells exposed to sublethal doses of ionizing radiation undergo a protective response that increases their resistance to subsequent irradiation.
  • a component of this protective response is formation of enlarged lysosomes or other acidified vacuolar organelles; inhibition of the vacuolar ATPase responsible for acidifying lysosomes with bafilomycin A prevents the protective response in sublethally irradiated cells and sensitizes cancer cells to ionizing radiation
  • Lysosomal damage is a significant mediator of radiation-induced death in cancer cells.
  • compounds of the invention are useful for reducing resistance of cancer cells to therapeutic ionizing radiation and for potentiating anticancer effectiveness of ionizing radiation therapy.
  • Compounds of the invention are optionally administered prior to ionizing radiation therapy of cancer (whether with external irradiation or administration of antibody-targeted radioisotopes) as radiosensitizers, or they may be given after irradiation to attack surviving cancer cells undergoing protective responses to nonlethal irradiation involving production or enlargement of acidic vacuoles.
  • One mechanism imparting selective survival and proliferation advantages in some cancers is upregulation of autophagy, a process through which damaged organelles or other cell debris are engulfed by autophagosomes, which fuse with lysosomes to digest and recycle constituent molecules.
  • autophagy a process through which damaged organelles or other cell debris are engulfed by autophagosomes, which fuse with lysosomes to digest and recycle constituent molecules.
  • compounds of the invention impair autophagy in cancer cells, thereby reducing their viability and resistance to other anticancer treatments.
  • compounds of the invention are administered by oral or intravenous administration in doses of 10 to 2000 milligrams per day.
  • Compounds of the invention are administered as single agents or in combination with other cancer treatments appropriate for a particular type of cancer, and generally in doses when such agents are used alone, as compounds of the invention will generally not have overlapping toxicities with other classes of anticancer agents that would necessitate substantial dose reduction.
  • This invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a biologically active agent as described herein and a pharmaceutically acceptable carrier.
  • Further embodiments of the pharmaceutical composition of this invention comprise any one of the embodiments of the biologically active agents described above. In the interest of avoiding unnecessary redundancy, each such agent and group of agents is not being repeated, but they are incorporated into this description of pharmaceutical compositions as if they were repeated.
  • the composition is adapted for oral administration, e.g. in the form of a tablet, coated tablet, dragee, hard or soft gelatin capsule, solution, emulsion or suspension.
  • oral composition will comprise from 10 to 1000 mg of the compound of this invention. It is convenient for the subject to swallow one or two tablets, coated tablets, dragees, or gelatin capsules per day.
  • the composition can also be adapted for administration by any other conventional means of systemic administration including rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions, or nasally.
  • the biologically active compounds can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical compositions.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatin capsules.
  • Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active ingredient no carriers are, however, usually required in the case of soft gelatin capsules, other than the soft gelatin itself.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oils and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical compositions can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, coating agents or antioxidants. They can also contain still other therapeutically valuable substances, particularly anti-inflammatory or antifungal agents (depending on whether an inflammatory disease or a fungal infection or cancer are being addressed in a patient) that act through mechanisms other than those underlying the effects of the compounds of the invention.
  • compounds of the invention act through a unique mechanism not shared by other anticancer drugs, they are compatible with a large variety of concurrent therapies, including antimetabolites, anthracyclines, tyrosine kinase inhibitors, platinum drugs, or alkylating agents. Such agents, when orally active, are administered or coformulated to deliver quantities of drugs determined in previous clinical trials to be effective and adequately tolerated.
  • compounds of the invention are optionally administered by intravenous injection or infusion.
  • intravenous administration compounds of the invention are dissolved in suitable intravenous formulations as solutions or in lipid emulsions, using standard excipients known in the art as well-tolerated intravenous formulation ingredients and compositions. Suitable volumes and concentrations are selected for delivery of 10 to 2000 miligrams of compounds of the invention per day, depending on the specific requirements for a compound, and a disease condition as determined in clinical trials.
  • Liposomal formulations are optionally incorporated into liposomal formulations.
  • the lipophilic moieties of compounds of the invention permit their direct incorporation into lipid layers of lipososomes. Liposomes are advantageous in some conditions for intravenous administration due to improved efficacy and milder infusion reactions versus nonliposomal formulations. Liposomes are also suitable for inhalational delivery to treat fungal or parasitic infections of the lungs, or inflammation of the lungs and airways.
  • compounds of the invention are incorporated into liposomal delivery formulations with other drugs, including but not limited to antifungal agents such as liposomal amphotericin B, or anticancer agents such as liposomal doxorubicin.
  • compositions of the invention are applied topically in a pharmaceutically acceptable formulation.
  • the topical composition can be in various forms, including, but not limited to, a solution, spray, gel, liydrogel, lotion, cream, ointment, paste, or an emulsion in the form of liquid suspension, lotion, or cream.
  • the composition can also be applied via a dermal patch, or bandage which can be applied on the affected area as needed, to provide an extended exposure of the skin to the medication; in such formulations, appropriate standard topical medicament excipients and vehicles are suitable for delivering compounds of the invention.
  • Ointment bases can comprise one or more of hydrocarbons (paraffin wax, soft paraffin, microcrystalline wax, or ceresine), absorption bases (wool fat or beeswax), macrogo!s (polyethylene glycol), or vegetable oils.
  • Lotions and creams are water in oil or oil in water emulsions; the oil components can comprise long chain fatty acids, alcohols or esters, and optional contain biocompatible nonionic surfactants, Compounds of the invention are incorporated into topical vehicles in concentrations ranging from 0.01% to 5%, preferably 0.02 to 1%.
  • Compounds of the invention are applied to skin lesions once to three times per day for durations dependent on the rate of resolution of the condition.
  • inhalational formulas of compounds of the invention are suitable for treatment of some lung infections, including fungal infections or parasites residing in alveolar macrophages.
  • Excipients and inhalational drug delivery devices are known in the art and are useful for delivering compounds of the invention to treat lung infections, including cryptococcus and tuberculosis.
  • Compounds of the invention are advantageously coformulated with other antifungal or antiinflammatory agents for topical or systemic administration, particularly when both drugs are appropriately administered via the same route and schedule.
  • Compounds of the invention are compatible with standard formulations and excipients used for other topical or systemic antifungal or anti-inflammatory agents, including but not limited to ointments and tablets or capsules.
  • Advantageous drug categories for combination in topical anti-inflammatoty formulations include corticosteroids, calcineurin inhibitors and vitamin D analogues, and other agents known to have independent therapeutic acitivity in inflammatory skin conditions.
  • N-(8-Butoxyoctyl)phthalimide l-Butoxy-8-iodooctane (6.2 g, 20.2 mmol) and potassium phthalimide (3.73 g, 20.2 mmol) in 50 mL of DMF were mixed at 60-80 °C for 12 hr. The cooled mixture was concentrated, and the residue was partitioned between EA (3x300 mL) and 5%
  • N-(8-Butoxyoctyl)quinolin-4-amine A mixture of 8-butoxyoctan-l -amine (0.569 mg, 2.89 mmol), 4-chloroquinoline (710 mg, 4.33 mmol), TEA (5 mL, 36 mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 °C for 4 days. The mixture was cooled and partitioned between EA and 5% Na 2 C0 3 and brine, dried over Na 2 S0 4 , filtered, and concentrated. Purification by FC (60% EA/Hex + 2% TEA) gave 244 mg of oil.
  • Methanesulfonyl chloride (4.50 mL, 57.5 mmol) and TEA (8.30 mL, 59.2 mmol) were added, and a white precipitate formed quickly. After 2 hr, the mixture was diluted with EA and washed with H 2 0, saturated NaHC0 3 , brine, 1M HCl, and brine, and the organic phase was dried over MgS0 4 and concentrated.
  • N-(8-Methoxyoctyl)phthalimide A 9 1 mixture of 8-methoxyoctyl methanesulfonate and 8- methoxyoctan-l-ol (4.10 g) was taken up in 80 mL of DMF and potassium phthalimide (4.4 g, 24 mmol) was added. The mixture was heated at 80-100 °C for 4 hr. Then, the mixture was cooled, diluted with EA, and washed with H 2 0, twice with 0.1M HCl, and brine. The organic phase was dried over MgS0 4 and concentrated onto silica gel. SPE, eluting with 30% EA/Hex, gave 4.32 g of the product as a solid.
  • N-(8-Methoxyoctyl)quinolin-4-amine A mixture of 4-chloroquinoline (3.00 mmol), 8- methoxyoctan-1 -amine (233 mg, 1.46 mmol), DIEA (0.52 mL, 3.00), and 4 mL of IPA was heated at 135 °C for 16 hr in a sealed tube. The mixture was treated with additional 8- methoxyoctan-1 -amine (343 mg, 2.16 mmol) and heated for an additional 64 hr. Then, the mixture was treated with additional 8-methoxyoctan-l -amine (140 mg, 0.88 mmol) and heated for an additional 48 hr.
  • 6-(Hexyloxy)hexan-l-amine was made starting from 1,6-hexanediol following the method for the preparation of 10-(hexyloxy)decan-l-amine.
  • 6-Butoxyhexyl methanesulfonate A mixture of 6-butoxyhexan-l-ol (6.55 g, 37.6 mmol) and TEA (5.51 mL, 39.5 mmol) in 100 mL of DCM was cooled using an ice bath. Then,
  • 6-Butoxyhexan-l -amine Hydrazine monohydrate (1.3 mL, 27 mmol) was added to a mixture of /V-(6-butoxyhexyl)phthalimide (6.72 g, 22.2 mmol) and 100 mL of EtOH. The mixture was heated at reflux for 16 hr. Then, the mixture was cooled with an ice bath and stirred vigourously while 200 mL of Et 2 0 were added. The precipitate was filtered and washed with Et 2 0, and the organic phases were concentrated to give 4.2 g of amber oil.
  • N-(6-Butoxyhexyl)quinolin-4-amine A mixture of 6-butoxyhexan-l -amine (0.5 g, 2.9 mmol), 4- chloroquinoline (711 mg, 4.4 mmol), TEA (5 mL, 36 mmol), and 0.5 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 °C for 4 days. The mixture was cooled and partitioned between EA and 5% Na 2 C0 3 and brine, dried over Na 2 S0 4 , filtered, and
  • the aqueous phase was extracted with EA (2x150 mL), and the organic phases were washed with saturated NaHC0 3 , H 2 0, 1M HC1, H 2 0, and brine (100 mL each).
  • the organic phases were dried over anhydrous Na 2 S0 4 , filtered through a pad of silica gel, and concentrated to 52.2 g of pale yellow liquid.
  • N-(6-Butoxyhexyl)phthalimide Crude l-butoxy-6-iodohexane and potassium phthalimide (46 g, 249 mmol) in 300 mL of DMF were mixed at room temperature for 41 hr and at 60-80 °C for 24 hr. The cooled mixture was concentrated, and the residue was partitioned between EA (3x350 mL) and H 2 0, 5% Na 2 S 2 0 3 , H 2 0, and brine (100 mL each). The combined organic phases were dried over Na 2 S0 4 , filtered through a pad of silica gel, and concentrated. SPE (10% EA/Hex) gave 51.6 g of colorless liquid.
  • 6-Butoxyhexan-l -amine Hydrazine monohydrate (9.1 mL, 187 mmol) was added to a mixture of N-(6-butoxyhexyl)phthalimide (51.6 g, 170 mmol) and 900 mL of EtOH. The mixture was heated at reflux for 12 hr, and allowed to stand at room temperature for 3 days. Then, 250 mL of volatile material was removed by distillation. 1M HC1 (200 mL) was added to the still- warm pot residue. After cooling to room temperature, the precipitate was removed by filtration, washing with three 200 mL portions of 50% aqueous EtOH.
  • the filtrate was adjusted to pH 10 by adding NaOH pellets, concentrated, and taken up in 800 mL of DCM.
  • the aqueous phase was separated, and the organic phase was dried over anhydrous Na 2 S0 4 and concentrated.
  • the product fractions were concentrated and taken up in DCM.
  • the organic phase was separated, dried over anhydrous Na 2 S0 4 , and concentrated to give
  • the residue was taken up in 150 mL of acetone, sodium iodide (1.27 g, 8.47 mmol) was added, and the mixture was heated at reflux for 3 hr. Then, the mixture was cooled, the solvent was evaporated, and the residue was partitioned between EA (3x100 mL) and 5% Na 2 S 2 0 3 and H 2 0 (50 mL of each), and the organic phases were dried over Na 2 S0 4 , filtered through a pad of silica gel, and concentrated. The residue was taken up in 20 mL of NMP and potassium phthalimide (1.66 g, 8.97 mmol) was added.
  • the mixture was partitioned between EA (3x350 mL) and H 2 0 (3x100 mL) and brine (100 mL), and the organic phases were dried over Na 2 S0 4 and concentrated. Purification by SPE using 10% EA/Hex gave 19.6 g of the azide product.
  • the azide was taken up in 40 mL of EA and 40 mL of MeOH under a blanket of argon, 2.0 g of 5% Pd/C were added, and the mixture was stirred under an atmosphere of hydrogen until the azide was consumed, as observed by TLC.
  • the catalyst was removed by filtration and the volatile components were evaporated.
  • the pot was partitioned between DCM and H 2 0, and the organic phase was dried over MgS0 4 and concentrated by distillation at room pressure to leave 96 g of a 2.1: 1 mixture of 1,5-dibromopentane and DCM.
  • the dibromide was retreated with sodium methoxide.
  • the crude l-bromo-5-methoxypentane mixtures were combined and separated by SPE, washing with pentane to recover 1,5-dibromopentane and eluting with 10% Et 2 0/pentane to get 8.40 g of colorless liquid after concentration by distillation.
  • N-(5-Methoxypentyl)quinolin-4-amine A mixture of 5-methoxypentan-l -amine, 4- chloroquinoline (900 mg, 5.52 mmol), and DIEA (0.50 mL, 2.87 mmol) was heated at 130 °C in a sealed tube for 24 hr. The mixture was cooled and partitioned between EA and 5% Na 2 C0 3 and brine. The organic phases were dried over anhydrous Na 2 S0 4 and concentrated. SPE, washing with 40% EA/Hex + 2% TEA and eluting with 80% EA/Hex + 2% TEA, gave a solid.
  • N-[8-(Hexyloxy)octyl]-2-methylquinolin-4-amine A mixture of 8-(hexyloxy)octan-l-amine (479 mg, 2.09 mmol), 4-chloroquinaldine (575 mg, 3.25 mmol), and DIEA (1.00 mL, 5.74 mmol) was heated at 140 °C in a sealed tube for 4 days. Then, the volatile material was evaporated, and the residue was purified by FC (7% MeOH/DCM) to give 217 mg of N-[8- (hexyloxy)octyl]-2-methylquinolin-4-amine.
  • 3-(Hexyloxy)propyl methanesulfonate was prepared by the method used for the preparation of 3- phenoxybenzyl methanesulfonate, using 44.2 g of 3-(hexyloxy)propan-l-ol, 43 mL of TEA, and 24 mL of methanesulfonyl chloride in 540 mL of DCM.
  • the crude material was taken up in 450 mL of acetone and reacted with 55.7 g of sodium iodide at reflux for 4 hr. Then, the mixture was cooled and diluted with 1 volume of hexanes. The solid was filtered, and the filtrate was concentrated.
  • 1,5-Pentanediol (230 mL) was blanketed with argon, and 22.6 g of potassium metal was added in portions. The exothermic evolution of gas was moderated by cooling with an ice bath. Then, at room temperature, a mixture of the crude l-(3-iodopropoxy)hexane and 100 mL of DMA was added dropwise. After being stirred overnight, unreacted iodide was observed by TLC. Sodium hydride (7.4 g) was added in 2-gram portions with cooling by an ice bath. The mixture was allowed to stir at room temperature for 60 hr. Then, the mixture was cooled with an ice bath and neutralized by the addition of concentrated HC1.
  • 5-Azidopentyl 3-(hexyloxy)propyl ether (29.3 g) was produced from the reaction of 5-[3- (hexyloxy)propoxy]pentyl methanesulfonate (51 g) and sodium azide (11.3 g) in 80 mL of DMF at room temperature following the method used for 8-(3-ethoxypropoxy)octan-l -amine.
  • N- ⁇ 5-[3-(Hexyloxy)propoxy]pentyl ⁇ quinolin-4-amine A mixture of 5-[3- (hexyloxy)propoxy]pentan-l -amine (482 mg, 1.97 mmol), 4-chloroquinoline (345 mg, 2.12 mmol), DEA (0.80 mL, 4.59 mmol), and 2 mL of NMP were heated at 160 °C for 3 days in a sealed tube. Then, the mixture was cooled, the volatile material was evaporated, the residue was partitioned between DCM and 5% Na 2 C0 3 , and the organic phase was dried over Na 2 S0 4 and concentrated.
  • N- ⁇ 3-[5-(Hexyloxy)pentyloxy]propyl ⁇ quinolin-4-amine (426 mg) was made by a method analogous to that used for the preparation of N- ⁇ 5-[3-(hexyloxy)propoxy]pentyl ⁇ quinolin-4- amine , but the two diols were reacted in the reverse sequence.
  • N-[8-(3-Ethoxypropoxy)octyl]quinolin-4-amine A mixture of 8-(3-ethoxypropoxy)octan-l- amine (1.0 g, 4.4 mmol), 4-chloroquinoline (1.46 g, 9.0 mmol), TEA (4.0 mL, 28 mmol), and 0.2 mL of NMP was sealed in a heavy walled glass tube and mixed at 130 °C for 4 days.
  • N-[8-(2-Propoxyethoxy)octyl]quinolin-4-amine (550 mg) was made using ethylene glycol monopropyl ether (2.00 mL, 17.5 mmol), 1,8-dibromooctane (25.7 mL, 139 mmol), and 4- chloroquinoline (1.42 g) using the method for the preparation of /V-[8-(3- ethoxypropoxy) octyl] quinolin-4- amine .
  • 8-(Benzyloxy)octan-l-amine (880 mg) was prepared from 8-(benzyloxy)octan-l-ol (4.23 g) following the method used in the preparation of 10-(hexyloxy)decan-l-amine.
  • N-(6-Phenoxyhexyl)quinolin-4-amine (188 mg) was prepared starting from 1,6-dibromohexane (4.25 mL) and phenol (326 mg) following the method used for the preparation of N-(8- phenoxyoctyl)quinolin-4-amine.
  • (6-Bromohexyloxy)benzene (409 mg): R/0.46 (5% EA/Hex); 1H NMR (CDC1 3 ) ⁇ 7.3 (m, 2H), 6.9 (m, 3H), 4.0 (m, 2H), 3.4 (m, 2H), 2.0-1.7 (m, 4H), 1.6-1.4 (m, 4H).
  • N- ⁇ 3-[2-(Hexyloxy)phenoxy]propyl ⁇ phthalimide A mixture of 2-(hexyloxy)phenol that contained l,2-bis(hexyloxy)benzene (90 mol % pure, 61.8 g), K 2 C0 3 (43.6 g, 316 mmol), and N- (3-bromopropyl)phthalimide (76.9 g, 287 mmol) in 150 mL of DMF was heated at 60 °C for 24 hr with the aid of mechanical stirring. TLC (5% EA, 45% toluene, 50% Hex) of an aliquot showed that substantial bromide starting material remained, so the temperature was raised to 100 °C.
  • the liquid was taken up in 400 mL of DCM and washed with IN NaOH and H 2 0 (100 mL each). The organic phase was concentrated. The mixture was separated by SPE. Elution with 1% MeOH/DCM gave 20 g of a mixture of 2- (hexyloxy)phenol and l,2-bis(hexyloxy)benzene. Then, elution with 7% MeOH/DCM + 2% NH 4 OH gave the product. The partially concentrated fractions were washed with 200 mL of H 2 0, the water phase was extracted with 150 mL of DCM, and the combined organic phases were dried over Na 2 S0 4 , filtered, and concentrated to give 33.6 g of an amber liquid.
  • N-(4-Bromobutyl)phthalimide A mixture of 1,4-dibromobutane (22 mL, 185 mmol) and potassium phthalimide (11.35 g, 61.4 mmol) in 60 mL of DMF was mixed at room temperature for 1 day. Then, the reaction mixture was extracted with hexane (3x150 mL). The hexane fractions were dried over MgS0 4 , filtered, and concentrated to give 30 g of a 1:2.2 molar mixture of recovered 1,4-dibromobutane and DMF.
  • This mixture was diluted with 30 mL of DMF and retreated with potassium phthalimide (4.80 g, 26 mmol) at room temperature for 1 day.
  • the two reaction mixtures in DMF were partitioned between 1: 1 EA/Hex (3x150 mL) and H 2 0 (2x100 mL), 0.1M HCl (100 mL), and brine (100 mL).
  • the organic phases were dried over MgS0 4 and concentrated. SPE, eluting with 0% and 10% EA/Hex, gave 17.3 g of colorless solid.
  • N- ⁇ 4- [2- (Hexyloxy)phenoxy] butyl ⁇ phthalimide A mixture of N- (4-bromobutyl)phthalimide (17.3 g, 61.3 mmol), 2-(hexyloxy)phenol (14.9 g, 61 mmol), and K 2 C0 3 (9.5 g, 69 mmol) in 80 mL of DMF was heated at 80 °C for 20 hr.
  • N-[3-(2-Ethoxyphenoxy)propyl]quinolin-4-amine (217 mg) was prepared following the method for the preparation of N- ⁇ 3-[4-(hexyloxy)phenoxy]propyl ⁇ quinolin-4-amine, starting with 2- ethoxyphenol (1.5 g) and N-(3-bromopropyl)phthalimide (2.91 g).
  • N-[3-(2-Ethoxyphenoxy)propyl]phthalimide (2.57 g): 1H NMR (CDC1 3 ) ⁇ 7.85 and 7.75 (m, 4H, AA'BB'), 6.95-6.80 (m, 4H), 4.1-4.0 (m, 4H), 3.9 (t, 2H), 2.2 (m, 2H), 1.4 (t, 3H).
  • 3-(2-Methoxyphenoxy)propan-l-amine was prepared following the method for the preparation of 3-[4-(Hexyloxy)phenoxy]propan-l-amine, starting with 2-methoxyphenol (1.5 g) and N-(3- bromopropyl)phthalimide (3.2 g).
  • N-[3-(2-Methoxyphenoxy)propyl]phthalimide (3.19 g): 1H NMR (CDC1 3 ) ⁇ 7.8 and 7.7 (m, 4H, AA'BB'), 6.9-6.8 (m, 4H), 4.1 (t, 2H), 3.9 (t, 2H), 3.7 (s, 3H), 2.2 (m, 2H).
  • N-[3- (2-Methoxyphenoxy)pro yl] quinolin-4- amine A mixture of 3-(2- methoxyphenoxy)propan- 1 -amine (770 mg, 3.95 mmol), 4-chloroquinoline (777 mg, 4.77 mmol), 0.15 mL of NMP and 2 mL of TEA were heated at 130 °C in a sealed tube for 5 days. Then, the mixture was cooled and concentrated in vacuo. Purification by preparative TLC (5% MeOH/DCM) gave the product.
  • N- ⁇ 3-[2-(Benyloxy)phenoxy]propyl ⁇ quinolin-4-amine was prepared following the method for the preparation of N- ⁇ 3-[4-(hexyloxy)phenoxy]propyl ⁇ quinolin-4-amine, starting with 2- (benzyloxy)phenol (2.0 g) and N-(3-bromopropyl)phthalimide (2.68 g).
  • N- ⁇ 3-[2-(Benzyloxy)phenoxy]propyl ⁇ phthalimide (3.6 g): 1H NMR (CDC1 3 ) ⁇ 7.8 and 7.7 (m, 4H, AA'BB'), 7.5-7.3 (m, 4H), 7.0-6.8 (m, 5H), 5.1 (s, 2H), 4.1 (t, 2H), 3.9 (t, 2H), 2.2 (m, 2H).
  • l-(8-Bromooctyloxy)-3-methoxybenzene (1.28 g) was prepared by the same method used for 1- (8-bromooctyloxy)-3-methylbenzene using 3-methoxyphenol (638 mg, 5.14 mmol), 1,8- dibromooctane (14.3 g, 53 mmol), and K 2 C0 3 (852 mg, 6.17 mmol) in 14 mL of NMP and 7 mL of DME heated for 24 hr.
  • N-[8-(3-Methoxyphenoxy)octyl]phthalimide (1.0 g) was prepared from l-(8-iodooctyloxy)-3- methoxybenzene (1.47 g, 4.06 mmol) and potassium phthalimide (1.13 g) in 50 mL of DMF at 60-80 °C for 12 hr following the method for N-[8-(hexyloxy)octyl]phthalimide.
  • N-[8-(3-Methoxyphenoxy)octyl]quinolin-4-amine 200 mg was prepared from 8-(3- methoxyphenoxy)octan-l -amine (438 mg, 1.74 mmol), 4-chloroquinoline (572 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4- amine.
  • the liquid was taken up in 100 mL of DCM and washed with IN NaOH and H 2 0 (10 mL each). The organic phase was concentrated. SPE, washing with 1% MeOH/DCM and then eluting with 7% MeOH/DCM + 2% NH 4 OH, gave the product. The partially concentrated fractions were washed with 20 mL of H 2 0, the water phase was extracted with 40 mL of DCM, and the combined organic phases were dried over Na 2 S0 4 and concentrated to give 763 mg of an amber liquid.
  • the mixture was partitioned between 1 : 1 EA/Hex and H 2 0 (3x), 0.1M HC1, and brine, and the organic phases were dried over Na 2 S0 4 , filtered, and concentrated.
  • the residue in 10% EA/Hex was filtered through a pad of silica gel, and then most of the solvents were evaporated. Vacuum distillation was performed to remove most of the excess dibromide, and the pot residue consisted of almost colorless solid and a small amount of liquid.
  • the pot was rinsed twice with Hex and the solid was dried in vacuo.
  • N-[8-(4-Methoxyphenoxy)octyl]phthalimide A mixture of crude l-(8-bromooctyloxy)-4- methoxybenzene and potassium phthalimide (7.59 g, 41.0 mmol) in 60 mL of NMP was stirred at room temperature until the bromide was consumed, as shown by TLC analysis of an aliquot. Then, 30 mL of H 2 0 was added, and much of the volatile material was evaporated in vacuo. The residue was partitioned between 1: 1 EA/Hex and H 2 0 and brine. The organic phases were dried over Na 2 S0 4 , filtered, and concentrated to give 14.88 g of a colorless solid. R O. l l (10%
  • N-[8-(4-Methoxyphenoxy)octyl]quinolin-4-amine 8-(4-Methoxyphenoxy)octan- 1-amine (4.60 g, 18.3 mmol) was taken up in 100 mL of 1-pentanol, and 30 mL of volatile material was removed by distillation. The mixture was cooled below boiling, and tripropylamine (7.00 mL, 36.7 mmol) and 4-chloroquinoline (3.28 g, 20.1 mmol) were added. Heating at reflux was resumed. After 26.25 hr, the mixture was cooled, and 20 mL of IN NaOH was added. Volatile material was removed by evaporation.
  • the solid had mp 141.0-144.0 °C.
  • the solid was dissolved in minimal hot butanone and then the mixture was allowed to cool to room temperature. After chilling in an ice bath for 2 hr, the precipitate was collected and washed with ice-cold butanone to give 3.98 g of a tan solid. R 0.23 (5%
  • N-[6-(4-Methoxyphenoxy)hexyl]quinolin-4-amine Four mL of pyridine was evaporated from 6- (4-methoxyphenoxy)hexan- 1 -amine (448 mg, 2.01 mmol). Then, a mixture of the amine, 4- chloroquinoline (424 mg, 2.60 mmol), DIEA (0.80 mL, 4.59 mmol), and 1.5 mL of NMP was heated at 160 °C in a sealed tube for 24 hr. The mixture was cooled and partitioned between DCM and 5% Na 2 C0 3 . The organic phase was dried over anhydrous Na 2 S0 4 and concentrated.
  • 4-(Hexyloxy)phenol was prepared by methods similar to that used for the preparation of 3- (hexyloxy)phenol. 4-(Benzyloxy)phenol (11.45 g), K 2 C0 3 (8.68 g), 1-bromohexane (10.4 mL), and DMF (50 mL) at 80-100 °C gave l-(benzyloxy)-4-(hexyloxy)benzene (12.97 g).
  • 2-[4-(Hexyloxy)phenoxy]ethanamine was prepared by the method used for the preparation of [3- (hexyloxy)phenyl] methanamine .
  • 2-[4-(Hexyloxy)phenoxy]ethanol (11.4 g)
  • methanesulfonyl chloride 5.60 mL
  • TEA 11.0 mL
  • DCM 150 mL
  • 2-[4-(hexyloxy)phenoxy]ethyl methanesulfonate (13.9 g).
  • N- ⁇ 3-[4-(Hexyloxy)phenoxy]propyl ⁇ phthalimide A mixture of 4-(hexyloxy)phenol (1.04 g, 5.36 mmol), N-(3-bromopropyl)phthalimide (1.44 g, 5.37 mmol), K 2 C0 3 (1.12 g, 8.12 mmol), and 10 mL of DMF was reacted for 26 hr. Then, the mixture was diluted with EA and washed with H 2 0, 0.1M HC1, and brine, dried over anhydrous Na 2 S0 4 , and concentrated.
  • l-(8-Azidoocyloxy)-3-methylbenzene (1.7 g) was prepared from l-(8-bromooctyloxy)-3- methylbenzene (1.7 g, 5.69 mmol) and sodium azide (740 mg, 11.4 mmol) in 50 mL of DMF following the method for the preparation of 10-butoxydecan-l -amine.
  • N-[8-(m-Tolyloxy)octyl]quinolin-4-amine (166 mg) was prepared from 8-(m-tolyloxy)octan-l- amine (0.6 g), 4-chloroquinoline (840 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4-amine.
  • l-(8-Bromooctyloxy)-4-methylbenzene (1.9 g) was prepared by the same method used for l-(8- bromooctyloxy)-3-methylbenzene using p-cresol (1.00 mL, 9.54 mmol), 1,8-dibromooctane (15.0 mL, 51 mmol), and K 2 C0 3 (2.6 g, 18.8 mmol) in 20 mL of NMP and 10 mL of DME heated for 66 hr.
  • N-[8-(p-Tolyloxy)octyl]quinolin-4-amine (161 mg) was prepared from 8-(p-tolyloxy)octan-l- amine (0.6 g), 4-chloroquinoline (840 mg), TEA (2 mL), and NMP
  • l-(8-Bromooctyloxy)-2-methylbenzene (1.3 g) was prepared by the same method used for l-(8- bromooctyloxy)-3-methylbenzene using ocresol (696 mg, 6.44 mmol), 1,8-dibromooctane (14 g, 81 mmol), and K 2 C0 3 (1.00 g, 7.25 mmol) in 12 mL of NMP and 12 mL of DME heated for 16 hr.
  • l-(8-Iodooctyloxy)-2-methylbenzene (1.3 g) was prepared from l-(8-bromooctyloxy)-2- methylbenzene (1.3 g, 4.35 mmol) and sodium iodide (652 mg, 4.35 mmol) in 50 mL of acetone following the method used in the preparation of 10-(hexyloxy)decan-l-amine.
  • N-[8-(o-Tolyloxy)octyl]phthalimide (1.3 g) was prepared from l-(8-iodooctyloxy)-2- methylbenzene (1.3 g) and potassium phthalimide (1.0 g, 5.4 mmol) in 50 mL of DMF following the method for N-[8-(hexyloxy)octyl]phthalimide.
  • 8-(o-Tolyloxy)octan-l-amine (390 mg) was prepared from N-[8-(o-tolyloxy)octyl]phthalimide (1.0 g, 2.74 mmol) using hydrazine monohydrate (0.2 mL) in EtOH (50 mL) following the method for [3-(hexyloxy)phenyl]methanamine.
  • 1H NMR (DMSO-d 6 ) ⁇ 7.1 (m, 2H), 6.9-6.75 (m, 2H), 3.9 (t, 2H), 2.5 (m, 2H), 2.15 (s, 3H), 1.75 (m, 2H), 1.5-1.2 (m, 10H).
  • N-[8-(o-Tolyloxy)octyl]quinolin-4-amine (300 mg) was prepared from 8-(otolyloxy)octan-l- amine (390 mg), 4-chloroquinoline (544 mg), TEA (2 mL), and NMP (0.2 mL) following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4-amine.
  • l-(8-Bromooctyloxy)-4-ieri-butylbenzene (900 mg) was prepared by the same method used for l-(8-bromooctyloxy)-3-methylbenzene using 4-ieri-butylphenol (647 mg, 4.31 mmol), 1,8- dibromooctane (11.7 g, 43 mmol), and K 2 C0 3 (714 mg, 5.17 mmol) in 12 mL of NMP and 6 mL of DME heated for 24 hr.
  • l-ie/ -Butyl-4-(8-iodooctyloxy)benzene (900 mg) was prepared from l-(8-bromooctyloxy)-4- ieri-butylbenzene (900 mg) and sodium iodide (400 mg) in 50 mL of acetone following the method for the preparation of 10-(hexyloxy)decan- l -amine.
  • N-[8-(4-ieri-Butylphenoxy)octyl]phthalimide (1.3 g) was prepared from l-ie/ -butyl-4-(8- iodooctyloxy)benzene (900 mg) and potassium phthalimide (860 mg) in 50 mL of DMF following the method for the preparation of N-[8-(hexyloxy)octyl]phthalimide.
  • 8-(4-ieri-Butylphenoxy)octan-l -amine (590 mg) was prepared from N-[8-(4-tert- butylphenoxy)octyl] phthalimide (900 mg) and hydrazine monohydrate (0.17 mL) in 50 mL of EtOH following the method for the preparation of [3-(hexyloxy)phenyl]methanamine.
  • 1H NMR (DMSO-d 6 ) ⁇ 7.25 and 6.80 (m, 4H, AA'BB'), 3.9 (t, 2H), 2.5 (m, 2H), 1.68 (m, 2H), 1.5-1.2 (m, 19H).
  • l-(8-Bromooctyloxy)-4-fluorobenzene (2.75 g) was prepared by the same method used for l-(8- bromooctyloxy)-3-methylbenzene using 4-fluorophenol (1.33 g, 12.1 mmol), 1,8-dibromooctane (20 mL, 108 mmol), and K 2 C0 3 (1.77 g, 14.3 mmol) in 20 mL of NMP and 10 mL of DME heated for 24 hr.
  • l-Fluoro-4-(8-iodooctyloxy)benzene was prepared from l(8-bromooctyloxy)-4-fluorobenzene (2.75 g, 9.08 mmol) and sodium iodide (1.63 g, 10.9 mmol) in 70 mL of acetone following the method used in the preparation of 10-(hexyloxy)decan-l-amine.
  • N-[8-(4-Fluorophenoxy)octyl]phthalimide (2.19 g) was prepared from l-fluoro-4-(8- iodooctyloxy)benzene and potassium phthalimide (2.52 g, 13.6 mmol) in 50 mL of DMF at 60- 80 °C for 12 hr following the method for N-[8-(hexyloxy)octyl]phthalimide.
  • N-[8-(4-Fluorophenoxy)octyl]quinolin-4-amine was prepared from 8-(4-fluorophenoxy)octan-l- amine (657 mg, 2.75 mmol), 4-chloroquinoline (676 mg), TEA (2 mL), and NMP (0.2 mL) at 130 °C in a sealed tube for 5 days following the method for N-[8-(3- ethoxypropoxy)octyl]quinolin-4-amine.
  • l-(8-Bromooctyloxy)-3-fluorobenzene (2.06 g) was prepared by the same method used for l-(8- bromooctyloxy)-3-methylbenzene using 3-fluorophenol (1.60 g, 14.3 mmol), 1,8-dibromooctane (25 mL, 135 mmol), and K 2 C0 3 (2.56 g, 18.5 mmol) in 25 mL of NMP and 12 mL of DME heated for 24 hr.
  • l-Fluoro-3-(8-iodooctyloxy)benzene was prepared from l-(8-bromooctyloxy)-3-fluorobenzene (2.06 g, 6.78 mmol) and sodium iodide (1.22 g, 8.13 mmol) in 60 mL of acetone following the method used in the preparation of 10-(hexyloxy)decan-l-amine.
  • N-[8-(3-Fluorophenoxy)octyl]phthalimide (1.85 g) was prepared from l-fluoro-3-(8- iodooctyloxy)benzene and potassium phthalimide (1.9 g, 10.3 mmol) in 50 mL of DMF at 60-80 °C for 12 hr following the method for N-[8-(hexyloxy)octyl]phthalimide.
  • 8-(3-Fluorophenoxy)octan-l-amine (874 mg, 3.66 mmol) was prepared from N-[8-(3- fluorophenoxy)octyl]phthalimide (1.85 g, 5.01 mmol) using hydrazine monohydrate (0.36 mL) in EtOH (50 mL) following the method for [3-(hexyloxy)phenyl]methanamine.
  • N-[8-(3-Fluorophenoxy)octyl]quinolin-4-amine was prepared from 8-(3-fluorophenoxy)octan-l- amine (874 mg, 3.66 mmol), 4-chloroquinoline (900 mg), TEA (2 mL), and NMP (1 mL) at 130 °C in a sealed tube for 5 days following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4- amine.
  • l-(8-Bromooctyloxy)-2-fluorobenzene (2.97 g) was prepared by the same method used for l-(8- bromooctyloxy)-3-methylbenzene using 2-fluorophenol (1.69 g, 15.1 mmol), 1,8-dibromooctane (38.3 g, 141 mmol), and K 2 C0 3 (2.76 g, 20 mmol) in 25 mL of NMP and 20 mL of DME heated for 24 hr.
  • l-Fluoro-2-(8-iodooctyloxy)benzene (3.43 g) was prepared from l-(8-bromooctyloxy)-2- fluorobenzene (2.97 g, 9.80 mmol) and sodium iodide (1.76 g, 11.7 mmol) in 70 mL of acetone following the method used in the preparation of 10-(hexyloxy)decan-l-amine.
  • Il l N-[8-(2-Fluorophenoxy)octyl]phthalimide (2.84 g) was prepared from l-fhioro-2-(8- iodooctyloxy)benzene (3.43 g) and potassium phthalimide (2.72 g, 14.7 mmol) in DMF at 60-80 °C for 12 hr following the method for N-[8-(hexyloxy)octyl]phthalimide.
  • 8-(2-Fluorophenoxy)octan-l -amine (1.27 g, 5.32 mmol) was prepared from N-[8-(2- fluorophenoxy)octyl]phthalimide (2.84 g, 7.70 mmol) using hydrazine monohydrate (0.50 mL) in EtOH (50 mL) following the method for [3-(hexyloxy)phenyl]methanamine.
  • N-[8-(2-Fluorophenoxy)octyl]quinolin-4-amine (100 mg) was prepared from 8-(2- fluorophenoxy)octan-l -amine (1.27 g, 5.32 mmol), 4-chloroquinoline (1.3 g, 7.98 mmol), TEA (2 mL), and NMP (1 mL) at 130 °C in a sealed tube for 5 days following the method for N-[8-(3- ethoxypropoxy)octyl]quinolin-4-amine.
  • Hexyl 4-aminobenzoate (282 mg), prepared from 1-hexanol and 4-nitrobenzoyl chloride in two unremarkable steps, was reacted with 4-chloroquinoline (322 mg) and DIEA (0.50 mL) in 2 mL of NMP heated at 160 °C in a sealed tube for 16 hr. The mixture was cooled and partitioned between EA and 5% Na 2 C0 3 . The organic phases were washed with brine, dried over Na 2 S0 4 , and concentrated. Purification by SPE, washing with 20% EA/Hex and then eluting with 55% EA/Hex, gave a yellow solid. Recrystallization from EA/Hex gave a colorless solid.
  • N-(4-Aminophenyl)hexanamide A mixture of N-(4-nitrophenyl)hexanamide (1.50 g), 10% Pd-C (200 mg), and 75 mL of MeOH was stirred under a blanket of hydrogen until the starting material was consumed, as observed by analytical TLC. Then, the atmosphere was purged with argon, and the mixture was filtered through a pad of Celite. Evaporation of the solvent gave 1.22 g of product.
  • N-[4-(Quinolin-4-ylamino)phenyl]hexanamide A mixture of 4-chloroquinoline (358 mg, 2.20 mmol), N-(4-aminophenyl)hexanamide (300 mg, 1.46 mmol), and TEA (1 mL) was heated at 130 °C in a sealed tube for 5 days. Then the volatile components were evaporated. The residue was purified by preparative TLC (10% MeOH/DCM) to give 329 mg of product.
  • N-[3-(Quinolin-4-ylamino)phenyl]hexanamide was prepared following the method for N-[4- (quinolin-4-ylamino)phenyl]hexanamide, starting with 3-nitroaniline (800 mg) and hexanoyl chloride (0.81 mL) and using 4-chloroquinoline (358 mg).
  • N-(4-Nitrophenyl)hexanamide (1.50 g): 1H NMR (CDC1 3 ) ⁇ 8.4 (m, IH), 8.0-7.9 (m, 2H), 7.8 (br s, IH, NH), 7.5 (m, IH), 2.4 (m, 2H), 1.8 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
  • N-(4-Aminophenyl)hexanamide (1.34 g): 1H NMR (CDC1 3 ) ⁇ 7.4 (br s, IH, NH), 7.2 (br s, IH), 7.0 (t, IH), 6.7 (d, IH), 6.4 (d, IH), 3.5 (br s, 2H, NH 2 ), 2.3 (t, 2H), 1.7 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
  • N-[3-(Quinolin-4-ylamino)phenyl]hexanamide R 0.2 (10% MeOH/DCM); 1H NMR (CD 3 OD) ⁇ 8.5 (d, IH), 8.4 (d, IH), 8.0-7.8 (m, 3H), 7.7 (m, IH), 7.5-7.3 (m, 2H), 7.1 (m, IH), 7.0 (d, IH), 2.4 (t, 2H), 1.7 (m, 2H), 1.4-1.2 (m, 4H), 0.9 (m, 3H).
  • N-Hexyl-4-(quinolin-4-ylamino)benzamide 4-Amino-N-hexylbenzamide (220 mg), prepared from 1-aminohexane (0.70 mL) and 4-nitrobenzoyl chloride (450 mg) in two unremarkable steps, was reacted with 4-chloroquinoline (239 mg) and DIEA (0.50 mL) in 1 mL of IPA heated at 130- 180 °C in a sealed tube for 8 days. The mixture was cooled and partitioned between DCM and 5% Na 2 C0 3 . The organic phases were dried over Na 2 S0 4 , and concentrated.
  • N-Hexyl-3-(quinolin-4-ylamino)benzamide (117 mg) was prepared following the method for N- hexyl-4-(quinolin-4-ylamino)benzamide, starting from 3-nitrobenzoic acid (1.17 g) and 1- hexylamine (1.02 mL) and using 4-chloroquinoline (225 mg).
  • N-[4-(Hexyloxy)phenyl]quinolin-4-amine A mixture of 4- (hexyloxy) aniline (430 mg, 2.23 mmol), 4-chloroquinoline (431 mg, 2.64 mmol), and DIEA (1.0 mL, 5.74 mmol) in 1 mL of NMP was heated in a heavy walled sealed tube at 160 °C for 24 hr. The mixture was cooled and partitioned between EA and 5% Na 2 C0 3 and brine. The organic phases were dried over Na 2 S0 4 and concentrated to give a solid that was recrystallized from EtOH to give a colorless solid.
  • 2-Fluoro-4-(hexyloxy)-l-nitrobenzene (2.6 g) was prepared from 3-fluoro-4-nitrophenol (5.0 g, 31.5 mmol), 60% sodium hydride (1.9 g), 1-bromohexane (4.75 mL), and 30 mL of DMF following the method for l-(8-bromooctyloxy)-3-methylbenzene.
  • N-[2-Fluoro-4-(hexyloxy)phenyl]quinolin-4-amine (114 mg) was prepared from 2-fhioro-4- (hexyloxy)aniline (1.6 g), 4-chloroquinoline (1.33 g), TEA (5 mL), and NMP (0.5 mL) at 130 °C in a sealed tube for 5 days following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4- amine.
  • the cooled mixture was diluted with 1 :2 DCM/EA and washed with 3N NaOH (60 mL), H 2 0, and brine.
  • the combined organic phases were dried over Na 2 S0 4 , filtered, and concentrated.
  • SPE eluting with 50% EA/Hex and then 15% EtOH/DCM, gave a brown oil.
  • the oil was taken up in EA and washed with 5% Na 2 C0 3 and brine.
  • the organic phase was dried over Na 2 S0 4 , filtered, and concentrated. EA (10 mL) and then hexanes (20 mL) were added to the residue. A precipitate was obtained.
  • the colorless precipitate was collected by filtration and washed with 100 mL of 50% EA/Hex and then 50 mL of 30% EA/Hex. A second crop was obtained from the combined filtrates. The crops were combined and dried in vacuo to give 38.4 g.
  • N-[3-(Hexyloxy)benzyl]phthalimide A mixture of 3-(hexyloxy)benzyl methanesulfonate and potassium phthalimide (15.4 g, 83.2 mmol) in 200 mL of DMF was stirred using a mechanical stirrer at room temperature for 4 hr and then at 50 °C for 4 hr. Then, H 2 0 (100 mL) was added, and the volatile material was evaporated. The residue was partitioned between EA and 5%
  • the mixture was diluted with DCM (350 mL) and washed with IN NaOH (50 mL) and 5% Na 2 C0 3 (50 mL).
  • the aqueous phases were extracted with DCM (100 mL).
  • the combined organic phases were dried over Na 2 S0 4 , filtered, and concentrated.
  • the residue was partitioned between EA (400, 175 mL) and 5% Na 2 C0 3 and brine (50 mL each).
  • the combined organic phases were dried over Na 2 S0 4 , filtered, and concentrated to approximately 50 mL, whereupon substantial precipitate formed.
  • N-[2-(Hexyloxy)benzyl]quinolin-4-amine A mixture of [2-(hexyloxy)phenyl]methanamine (417 mg, 2.01 mmol), 4-chloroquinoline (430 mg, 2.64 mmol), and DIEA (0.50 mL, 2.86 mmol) in 1 mL of NMP was heated at 150 °C in a sealed tube for 18 hr. Then, the mixture was cooled and partitioned between EA and 5% Na 2 C0 3 and brine. The organic phase was dried over Na 2 S0 4 and concentrated. SPE, washing with 2.5% MeOH/DCM and then eluting with 7% MeOH/DCM, gave 545 mg of solid.
  • [3-Fluoro-4-(hexyloxy)phenyl]methanamine (212 mg, 0.9 mmol) was prepared from 3-fluoro-(4- hexyloxy)benzonitrile (721 mg, 3.3 mmol) and LAH (6.6 mmol) in THF (50 mL) at 0 °C for 4 hr and room temperature for 12 hr following the method for [4-(hexyloxy)phenyl]methanamine.
  • N-[3-Fluoro-4-(hexyloxy)benzyl]quinolin-4-amine (325 mg) was prepared from [3-fluoro-4- (hexyloxy)phenyl]methanamine (486 mg, 2.2 mmol), 4-chloroquinoline (541 mg, 3.3 mmol), TEA (4 mL), and NMP (0.5 mL) at 130 °C in a sealed tube for 5 days following the method for N-[8-(3-ethoxypropoxy)octyl]quinolin-4-amine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Agronomy & Crop Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PCT/US2014/013992 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity WO2014120995A2 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
AU2014212242A AU2014212242B2 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
RU2015137094A RU2677229C2 (ru) 2013-02-01 2014-01-31 Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность
NZ709885A NZ709885A (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
EP19201890.1A EP3632426A1 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
HK15112408.4A HK1211429B (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US14/764,207 US10030015B2 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
EP14746786.4A EP2950649B1 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
DK14746786.4T DK2950649T3 (da) 2013-02-01 2014-01-31 Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet
CN201480007029.0A CN104968200B (zh) 2013-02-01 2014-01-31 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
JP2015556146A JP6463276B2 (ja) 2013-02-01 2014-01-31 抗炎症、抗真菌、抗寄生生物及び抗癌活性を有するアミン化合物
ES14746786T ES2790675T3 (es) 2013-02-01 2014-01-31 Compuestos de amina que tienen actividad anti-inflamatoria, antifúngica, antiparasitaria y anticáncer
MX2015009864A MX369611B (es) 2013-02-01 2014-01-31 Compuestos de amina que tienen actividad anti-inflamatoria, antifungica, antiparasitaria y anticancer.
BR112015018282-8A BR112015018282B1 (pt) 2013-02-01 2014-01-31 Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
KR1020157023305A KR102205202B1 (ko) 2013-02-01 2014-01-31 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물
KR1020217000847A KR20210007046A (ko) 2013-02-01 2014-01-31 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물
PL14746786T PL2950649T3 (pl) 2013-02-01 2014-01-31 Związki aminowe o działaniu przeciwzapalnym, przeciwgrzybiczym, przeciwpasożytniczym i przeciwnowotworowym
CA2898018A CA2898018C (en) 2013-02-01 2014-01-31 Substituted quinolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
BR122021012629-1A BR122021012629B1 (pt) 2013-02-01 2014-01-31 Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
ZA2015/04954A ZA201504954B (en) 2013-02-01 2015-07-09 Amine compounds having anti-inflammatory,antifungal,antiparasitic and anticancer activity
IL24020515A IL240205B (en) 2013-02-01 2015-07-28 Amine compounds with anti-inflammatory, anti-fungal, anti-parasitic and anti-cancer activity
AU2018201239A AU2018201239A1 (en) 2013-02-01 2018-02-21 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US16/015,264 US20180298000A1 (en) 2013-02-01 2018-06-22 Aminoquinoline compounds having anticancer activity
US16/285,460 US10934284B2 (en) 2013-02-01 2019-02-26 Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
IL269583A IL269583B (en) 2013-02-01 2019-09-24 Amine compounds with anti-inflammatory, anti-fungal, anti-parasitic and anti-cancer activity
AU2020200510A AU2020200510B2 (en) 2013-02-01 2020-01-23 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US17/176,923 US12139483B2 (en) 2013-02-01 2021-02-16 Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
US18/906,289 US20250034139A1 (en) 2013-02-01 2024-10-04 Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759512P 2013-02-01 2013-02-01
US61/759,512 2013-02-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/764,207 A-371-Of-International US10030015B2 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
US16/015,264 Continuation US20180298000A1 (en) 2013-02-01 2018-06-22 Aminoquinoline compounds having anticancer activity

Publications (2)

Publication Number Publication Date
WO2014120995A2 true WO2014120995A2 (en) 2014-08-07
WO2014120995A3 WO2014120995A3 (en) 2014-10-16

Family

ID=51263115

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/013992 WO2014120995A2 (en) 2013-02-01 2014-01-31 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity

Country Status (17)

Country Link
US (5) US10030015B2 (enrdf_load_stackoverflow)
EP (2) EP2950649B1 (enrdf_load_stackoverflow)
JP (2) JP6463276B2 (enrdf_load_stackoverflow)
KR (2) KR102205202B1 (enrdf_load_stackoverflow)
CN (2) CN108250142B (enrdf_load_stackoverflow)
AU (2) AU2014212242B2 (enrdf_load_stackoverflow)
BR (2) BR112015018282B1 (enrdf_load_stackoverflow)
CA (3) CA3102531A1 (enrdf_load_stackoverflow)
DK (1) DK2950649T3 (enrdf_load_stackoverflow)
ES (1) ES2790675T3 (enrdf_load_stackoverflow)
IL (2) IL240205B (enrdf_load_stackoverflow)
MX (5) MX369611B (enrdf_load_stackoverflow)
NZ (1) NZ709885A (enrdf_load_stackoverflow)
PL (1) PL2950649T3 (enrdf_load_stackoverflow)
RU (2) RU2721418C2 (enrdf_load_stackoverflow)
WO (1) WO2014120995A2 (enrdf_load_stackoverflow)
ZA (1) ZA201504954B (enrdf_load_stackoverflow)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159672A1 (ja) * 2014-04-17 2015-10-22 株式会社ダイセル ハロゲン化合物の製造方法、カリウム塩の製造方法、及びカリウム塩
WO2016065283A1 (en) * 2014-10-24 2016-04-28 Bishop Alexander James Roy Methods and compositions for enhancing chemotherapy
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
JP2018035185A (ja) * 2017-10-13 2018-03-08 株式会社ダイセル カリウム塩の製造方法、及びカリウム塩
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2020142735A1 (en) 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
EP3972586A1 (en) * 2019-07-04 2022-03-30 Aberystwyth University Antibacterial and antiparasitic quinoxaline-2,3-diamine derivatives
US11396509B2 (en) 2019-04-17 2022-07-26 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11440898B2 (en) 2016-12-28 2022-09-13 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
US11583531B2 (en) 2019-04-17 2023-02-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2024049929A3 (en) * 2022-08-30 2024-10-17 Pannex Therapeutics Inc. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3102531A1 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US11364237B2 (en) * 2017-02-07 2022-06-21 Oncocross Co., Ltd. Composition for inhibiting cancer metastasis and treating cancer
JP7104134B2 (ja) * 2017-03-15 2022-07-20 ルネラ・バイオテック・インコーポレーテッド ミトリボシン：癌細胞、細菌、及び病原性酵母を標的とした、ミトコンドリアベースの治療薬
CN108084089B (zh) * 2017-12-08 2020-10-23 华南农业大学 一种防治白色念珠菌的2-烷基胺喹啉类化合物及其制备方法与应用
CN108892634B (zh) * 2018-06-19 2021-04-23 浙江工业大学 一种吲哚甲基苯胺类化合物及其应用
CN111892516A (zh) * 2018-08-08 2020-11-06 中国人民解放军总医院 抗肿瘤化合物
MX2021015652A (es) 2019-06-25 2022-02-03 Amtixbio Co Ltd Nuevo derivado del acido aminoalcanoico que contiene un grupo bifenilo y una composicion farmaceutica antifungica que comprende el mismo.
CN110804013B (zh) * 2019-10-09 2024-04-05 南京工业大学 一种邻位二胺类化合物的合成方法
US11919864B2 (en) * 2020-09-25 2024-03-05 Escient Pharmaceuticals, Inc. Modulators of Mas-related G-protein receptor X2 and related products and methods
WO2025069039A1 (en) * 2023-09-28 2025-04-03 Rajaram Samant An in situ process for the preparation of primary amine compounds
WO2025143877A1 (ko) * 2023-12-28 2025-07-03 (주)앰틱스바이오 아미노 니코틴아마이드 구조를 포함하는 유도체 화합물 및 이를 포함하는 항진균성 약학적 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4320294Y1 (enrdf_load_stackoverflow) 1964-10-31 1968-08-26
CH492395A (de) * 1966-04-26 1970-06-30 Sandoz Ag Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels
GB1496371A (en) * 1975-08-18 1977-12-30 Serdex 4-amino-quinoline derivatives process for their preparation and therapeutic applications thereof
GB1582407A (en) 1977-06-07 1981-01-07 Worcester Controls Uk Ltd Annular seals
JPS53103484A (en) * 1977-02-21 1978-09-08 Takeda Chem Ind Ltd Quinazoline derivatives, process for their preparation and nsecticedes and fungicides
JPS542325A (en) 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPS5576803A (en) * 1978-12-06 1980-06-10 Sankyo Co Ltd Agent for controlling noxious life
GB2068732B (en) * 1980-02-08 1983-06-02 Sandoz Ltd Ectoparasites compounds
US4331667A (en) * 1980-02-08 1982-05-25 Sandoz Ltd. Quinazolines for controlling ectoparasites
GB8306360D0 (en) 1983-03-08 1983-04-13 Sandoz Ltd Quinazolines
GB2135887A (en) 1983-03-08 1984-09-12 Sandoz Ltd 4-Alkylamino-quinazolines used as insecticides
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US5114939A (en) * 1988-01-29 1992-05-19 Dowelanco Substituted quinolines and cinnolines as fungicides
US5294622A (en) * 1988-01-29 1994-03-15 Dowelanco Substituted quinolines and cinnolines
IL89026A (en) * 1988-01-29 1993-02-21 Lilly Co Eli Substituted quinolines and cinnolines, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
US5278173A (en) * 1988-06-30 1994-01-11 Davis Michael H Method of inhibiting the activity of human immunodeficiency virus (HIV) in vivo
BR8907518A (pt) * 1988-06-30 1991-05-28 Michael H Davis Processo para inibir a atividade do virus da imunodeficiencia humana(hiv)in vivo
US5141941A (en) * 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
UA32546C2 (uk) * 1991-03-01 2001-02-15 Міннесота Майнінг Енд Мен'Юфекчурінг Компані 1,2-заміщені 1н-імідазо[4,5-с]хінолін-4-аміни, проміжні сполуки для їх синтезу, антивірусна фармацевтична композиція, спосіб лікування інфікованих ссавців, спосіб індукування біосинтезу інтерферону у ссавців, спосіб уповільнення росту бластом
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9612829D0 (en) * 1996-06-19 1996-08-21 Univ London Potassium channel blockers
DE19647317A1 (de) 1996-11-15 1998-05-20 Hoechst Schering Agrevo Gmbh Substituierte Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
SE0102858D0 (sv) 2001-08-27 2001-08-27 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
HUP0105406A3 (en) 2001-12-21 2003-12-29 Sanofi Aventis Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105407A3 (en) 2001-12-21 2004-04-28 Sanofi Aventis Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd NEW ANTIPILIC AGENT CONTAINING A HETEROCYCLIC COMPOUND
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
JP5019884B2 (ja) 2004-02-20 2012-09-05 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 炎症プロセスおよび転移プロセスの調節
US20060074105A1 (en) 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
ES2401099T3 (es) * 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US7928111B2 (en) 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009094528A1 (en) 2008-01-25 2009-07-30 High Point Pharmaceuticals, Llc TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
US20100120741A1 (en) 2008-09-10 2010-05-13 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP2012513464A (ja) * 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
DK2396307T3 (en) 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
CA2765823A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Tricyclic heterocyclic compounds as mediators of p13k activity
PH12012500097A1 (en) 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
JP2011026251A (ja) 2009-07-27 2011-02-10 Kowa Co ２−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
KR101467996B1 (ko) * 2010-04-30 2014-12-11 전북대학교산학협력단 에이디피-리보실 사이클라제 활성을 저해하는 퀴나졸린 유도체
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
CA2841452C (en) 2011-04-29 2021-04-13 The Trustees Of The University Of Pennsylvania Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
CA3102531A1 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015159672A1 (ja) * 2014-04-17 2015-10-22 株式会社ダイセル ハロゲン化合物の製造方法、カリウム塩の製造方法、及びカリウム塩
WO2016065283A1 (en) * 2014-10-24 2016-04-28 Bishop Alexander James Roy Methods and compositions for enhancing chemotherapy
US10231958B2 (en) 2014-10-24 2019-03-19 The Board Of Regents Of The University Of Texas System Methods and compositions for enhancing chemotherapy
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10285990B2 (en) 2015-03-04 2019-05-14 Gilead Sciences, Inc. Toll like receptor modulator compounds
US12377100B2 (en) 2015-03-04 2025-08-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11124487B2 (en) 2016-09-02 2021-09-21 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11827609B2 (en) 2016-09-02 2023-11-28 Gilead Sciences, Inc. Toll like receptor modulator compounds
US11440898B2 (en) 2016-12-28 2022-09-13 Minoryx Therapeutics S.L. Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
JP2018035185A (ja) * 2017-10-13 2018-03-08 株式会社ダイセル カリウム塩の製造方法、及びカリウム塩
WO2020142735A1 (en) 2019-01-04 2020-07-09 BellBrook Labs Inhibitors of cgas activity as therapeutic agents
EP3906229A4 (en) * 2019-01-04 2022-11-16 Bellbrook Labs, Llc INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENT
US11396509B2 (en) 2019-04-17 2022-07-26 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11583531B2 (en) 2019-04-17 2023-02-21 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
US11286257B2 (en) 2019-06-28 2022-03-29 Gilead Sciences, Inc. Processes for preparing toll-like receptor modulator compounds
EP3972586A1 (en) * 2019-07-04 2022-03-30 Aberystwyth University Antibacterial and antiparasitic quinoxaline-2,3-diamine derivatives
WO2024049929A3 (en) * 2022-08-30 2024-10-17 Pannex Therapeutics Inc. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Also Published As

Publication number Publication date
AU2018201239A1 (en) 2018-03-22
CN104968200B (zh) 2018-03-06
CA3217159A1 (en) 2014-08-07
US10030015B2 (en) 2018-07-24
JP6463276B2 (ja) 2019-01-30
WO2014120995A3 (en) 2014-10-16
EP2950649A4 (en) 2016-10-26
US20150361077A1 (en) 2015-12-17
MX2024007304A (es) 2024-08-28
NZ749999A (en) 2020-09-25
MX2024007308A (es) 2024-08-28
BR112015018282A2 (pt) 2017-07-18
RU2019100054A (ru) 2019-01-24
IL269583B (en) 2022-01-01
IL269583A (en) 2019-11-28
US20180298000A1 (en) 2018-10-18
KR102205202B1 (ko) 2021-01-21
ZA201504954B (en) 2016-07-27
RU2019100054A3 (enrdf_load_stackoverflow) 2019-08-09
HK1211429A1 (en) 2016-05-27
JP6724128B2 (ja) 2020-07-15
NZ709885A (en) 2019-07-26
US20190194193A1 (en) 2019-06-27
RU2677229C2 (ru) 2019-01-16
CN108250142B (zh) 2021-01-26
CA3102531A1 (en) 2014-08-07
KR20210007046A (ko) 2021-01-19
MX2019004884A (es) 2019-12-16
RU2721418C2 (ru) 2020-05-19
BR112015018282B1 (pt) 2021-08-24
EP2950649B1 (en) 2020-03-04
JP2016506965A (ja) 2016-03-07
AU2014212242A1 (en) 2015-09-17
CA2898018A1 (en) 2014-08-07
MX2024007306A (es) 2024-08-28
US10934284B2 (en) 2021-03-02
BR122021012629B1 (pt) 2022-06-07
CA2898018C (en) 2021-02-09
RU2015137094A (ru) 2017-03-09
US20210163476A1 (en) 2021-06-03
US20250034139A1 (en) 2025-01-30
US12139483B2 (en) 2024-11-12
DK2950649T3 (da) 2020-05-04
JP2019070002A (ja) 2019-05-09
ES2790675T3 (es) 2020-10-28
MX369611B (es) 2019-11-14
CN104968200A (zh) 2015-10-07
PL2950649T3 (pl) 2020-11-02
AU2014212242B2 (en) 2017-12-21
EP2950649A2 (en) 2015-12-09
KR20150112005A (ko) 2015-10-06
CN108250142A (zh) 2018-07-06
AU2020200510A1 (en) 2020-02-13
MX2015009864A (es) 2016-04-07
IL240205B (en) 2019-10-31
EP3632426A1 (en) 2020-04-08
IL240205A0 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
US12139483B2 (en) Imidazoquinolyl compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity
US10517871B2 (en) Survivin-targeting anti-tumor agents and uses thereof
AU2020200510B2 (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
HK40023680A (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
HK1211429B (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
NZ749999B2 (en) Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
US11274106B2 (en) Topoisomerase inhibitors with antibacterial and anticancer activity
US20250129083A1 (en) Imidazotetrazine compounds and treatment of tmz-resistant cancers
CN116528875A (zh) 具有抗炎、抗真菌、抗寄生虫和抗癌活性的咪唑并喹啉化合物
KR102070361B1 (ko) 중수소화 ｃｆｔｒ 강화제

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14746786

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2898018

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015556146

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 240205

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14764207

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/009864

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015018282

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157023305

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015137094

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014746786

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014212242

Country of ref document: AU

Date of ref document: 20140131

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14746786

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112015018282

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150730